Pre-Congress
Tuesday 26 May 2015
CONTINUING EDUCATION IN CLINICAL TOXICOLOGY: PRE-Congress Symposium

Pharmacology for toxicologists

09.00 Keynote lecture: Dose-effect relationships (including idiosyncratic reactions)
Stephan Krähenbühl
Clinical Pharmacology & Toxicology, University Hospital, Basle, Switzerland

At the end of this session the audience should be able to:
- describe a dose-effect and dose-toxicity relationship
- estimate the therapeutic range of a given drug
- define intrinsic and idiosyncratic toxicants

09.30 Keynote lecture: Kinetics: Absorption - different routes and their specificities
Evangelia Liakoni
Clinical Pharmacology & Toxicology, University Hospital, Basle, Switzerland

At the end of this session the audience should be able to:
- describe the characteristics of different administration routes (oral, intravenous, inhalation, transdermal, etc.)
- anticipate the influence of physicochemical properties of a drug on its absorption from different sites of administration
- understand how oral bioavailability (absorption and first-pass effect) are influenced by drug-drug interactions in pharmacology and toxicology

10.00 Keynote lecture: Role of transporters in drug disposition: Drug-drug interactions and decisional trees
Xavier Decleves
Department of Pharmaceutical Sciences, Inserm UMR-S1144 at University Paris Descartes, Paris, France

At the end of this session the audience should be able to:
- identify the main transporters expressed in human tissues involved in drug disposition (intestine, liver, kidneys, brain barriers)
- recognize significant clinical drug-drug interactions mediated by human drug transporters
- describe FDA and EMA guidelines regarding drug-drug interactions for a new medicine compound that interact with drug transporters and be able to use decisional trees

10.30 - 11.00 Coffee
11.00 Keynote lecture: Metabolism: Phase I and phase II enzymes including polymorphism  

**Gesche Jürgens**  
Unit of Clinical Pharmacology, Roskilde University Hospital, Roskilde, Denmark

At the end of this session the audience should be able to:
- explain the underlying mechanisms of phase I and II metabolism
- discuss the most important enzymes involved in phase I and II metabolism
- describe possible clinical and toxicological consequences of genetic polymorphism of drug metabolizing enzymes

11.30 Keynote lecture: Elimination: Renal clearance, enterohepatic circulation  

**Darren M Roberts**  
Drug Health Clinical Services, Royal Prince Alfred Hospital, Sydney, Australia

At the end of this session the audience should be able to:
- describe normal physiological processes that influence the excretion of xenobiotics and their metabolites
- discuss the influence of impaired kidney and biliary function on the disposition of xenobiotics and their metabolites
- list examples of therapeutic interventions that influence xenobiotic excretion in the poisoned patient

12.00 Keynote lecture: Modelling dose-concentration-response (I)  

**Ursula Gundert-Remy**  
Institute for Clinical Pharmacology and Toxicology, Charité Medical School, Berlin, Germany

At the end of this session the audience should be able to:
- recognize the difference between pharmaco-/toxicokinetics and -dynamics and understand how the two interact
- discuss the different approaches in modelling kinetics and dynamics of xenobiotics
- explain how to interpret data on dose-concentration-response data and how to use them in risk assessment

12.30 - 14.00 Lunch
14.00 Keynote lecture: Development of tolerance

Peter De Paepe\textsuperscript{1,2}

\textit{Department of Emergency Medicine, Ghent University Hospital, Ghent, Belgium; \textsuperscript{2} Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium}

At the end of this session the audience should be able to:

- summarize the basic principles of tolerance development
- explain the principles of addiction, dependence and withdrawal
- recognize the clinical consequences of tolerance

14.30 Keynote lecture: How to report on drug-drug interactions (checklist)

Philip A Routledge

\textit{Institute of Molecular and Experimental Medicine, Cardiff University, Cardiff, UK}

At the end of this session the audience should be able to:

- explain the major mechanisms underlying drug-drug interactions (DDIs)
- describe the European regulatory framework for investigation of possible DDIs
- list the main components of a checklist for the development of DDI management guidelines

15.00 Keynote lecture: EXTRIP - Practical considerations in performing kinetics during extracorporeal treatments

Marc Ghannoum

\textit{Nephrology Department at Verdun Hospital, University of Montreal, Montreal, Canada}

At the end of this session the audience should be able to:

- describe how to perform appropriate measurements during extracorporeal treatments
- use appropriate kinetic calculations for determination of dialyzability
- recognize common pitfalls in performing kinetic studies during extracorporeal treatments

\underline{15.30 - 16.00 Coffee}
Interactive case studies

16.00 Case 1 - Can the genotype help to identify the vulnerable poisoned patient?  
Kim Dalhoff  
Department of Clinical Pharmacology, Bispebjerg University Hospital, Copenhagen, Denmark

16.30 Case 2 - Life is not a Long Quiet River  
Bruno Mégarbane

1INSERM U1144, Paris-Descartes University, Paris, France; 2 Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris-Diderot University, Paris, France

17.00 Case 3 - Response to antivitamine K oral anticoagulants: how to manage the outliers?  
Marie-Anne Loriot  
INSERM UMR-S 1147, Université Paris Descartes, Paris, France

At the end of this session the audience should be able to:

- identify genotypes which may be relevant in the evaluation of the poisoned patient
- investigate drug-drug interactions to explain poisoning severity
- discuss the source of interindividual variability in VKA response and explain the genetic basis of this variability

17.30 Close
Main Congress
Wednesday 27 to Friday 29 May 2015
### Welcome and opening

**Alexander Campbell**  
*President, EAPCCT*

### Symposium: Toxic deaths

#### 08.35 PLENARY LECTURE

**Anthropology and forensic toxicology: how to revisit our history?**  
*Philippe Charlier*  
*Section of Medical and Forensic Pathology, UVSQ, Montigny-le-Bretonneux, France*

At the end of this session the audience should be able to:
- explain the usefulness of archeo-anthropological samples for enhancing and validation of toxicological analyses for forensic purposes
- summarize why well-documented cases are of great interest for establishing objective data for history of diseases and medico-surgical practices
- list reasons why inter-disciplinarity is an obligation for such retrospective diagnoses and individual identification processes

#### 09.20 Keynote lecture: Epidemiology of fatal poisonings: National Poison Data System (NPDS) data 2000-2014 (2)

*Alvin C Bronstein*\(^1,2\)

\(^1\)Department of Emergency Medicine, University of Colorado School of Medicine, Denver, USA;  
\(^2\)Rocky Mountain Poison Center, Denver Health, Denver, USA

At the end of this session the audience should be able to:
- list three categories of the NPDS Relative Contribution to Fatality (RFC) Rating Scale
- explain the difference between poisoning-related death and fatality
- describe NPDS fatality case volume trends over time from 2000-2014

#### 09.40 Keynote lecture: Toxic murder 2000-2014 (3)

*Robin E Ferner*  
*West Midlands Centre for Adverse Drug Reactions and University of Birmingham, Birmingham, UK*

At the end of this session the audience should be able to:
- recognize the wide range of poisons that has been used in the last fifteen years in murder or attempted murder
- discuss the difficulties of clinical and laboratory diagnosis of poisoning
- discuss whether systematic reporting would be desirable

---

**10.00 ÷ 10.30 Coffee and Posters**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Welcome and PLENARY LECTURE (Auditorium I)</td>
</tr>
<tr>
<td>09.20</td>
<td>Anthropology and forensic toxicology: how to revisit our history?</td>
</tr>
</tbody>
</table>

**Symposium: Toxicology in specific populations**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.20</td>
<td>Keynote lecture: Pregnancy and lactation</td>
</tr>
</tbody>
</table>

_Laura Yates_

*Regional Drug and Therapeutics Centre, UK Teratology Information Service, Newcastle upon Tyne, UK*

At the end of this session the audience should be able to:

- identify the risks to both mother and child of acute or chronic poisoning during pregnancy or lactation
- recognize and avoid common pitfalls in the management of the poisoned pregnant or lactating patient
- recognize and identify relevant specialist teratology and/or poisons advisory services through which expert advice can be obtained and which enable collection of longer term fetal outcome data

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.40</td>
<td>Keynote lecture: The challenge of obesity in toxicology</td>
</tr>
</tbody>
</table>

_Celia Lloret-Linares_

*INSERM U1144 Variabilité de réponse aux psychotropes, Université Paris Descartes-Paris Diderot, Paris, France*

At the end of this session the audience should be able to:

- discuss the many physiological changes affecting drug pharmacokinetics
- identify the factors that can alter drug pharmacodynamics
- identify the predictors of poor prognosis in obese patients

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00</td>
<td>Coffee and Posters</td>
</tr>
<tr>
<td>10.30</td>
<td>Coffee and Posters</td>
</tr>
</tbody>
</table>
Symposium: Toxic deaths ï Part 2

10.30  Keynote lecture: Toxic deaths: Facts and follies of forensic medicine (4)  
Michael G Holland  
Department of Emergency Medicine, SUNY Upstate Medical University, Syracuse, USA

At the end of this session the audience should be able to:
• describe the phenomenon of post-mortem redistribution (PMR) and what factors of an individual case make it likely that the forensic toxicology laboratory values can be explained by PMR
• list the major factors that influence the accuracy and reliability of a blood alcohol concentration (BAC) value, and how adjunctive specimens can aid in interpretation
• explain how the presence of specific short-lived analytes may implicate a particular drug as being the cause of death, even from a heart blood specimen

10.50  A simple prognostic model for predicting mortality in acute aluminium phosphide poisoning (5)  
Ashish K Bhalla, Laxman Jhuria, Navneet Sharma, Susheel Kumar, Surjit Singh  
Post Graduate Institute of Medical Education and Research, Chandigarh, India

11.05  Clinical characteristics of fatal salicylate poisonings (6)  
Helena L Frischtak¹, Joshua D King¹,²,³, J Priyanka Vakkalanka¹,², Christopher P Holstege¹,²  
¹School of Medicine, University of Virginia, Charlottesville, USA; ²Division of Medical Toxicology, University of Virginia, Charlottesville, USA; ³Division of Nephrology, University of Virginia, Charlottesville, USA

11.20  Clinical risk factors in Emergency Department (ED) patients with prescription opioid overdose (7)  
Lindsay Fox¹, Robert S Hoffman², David Vlahov³, Alex F Manini⁴  
¹Emergency Medicine Residency, the Icahn School of Medicine at Mount Sinai, New York, USA; ²Division of Medical Toxicology, NYU School of Medicine, New York, NY, USA.; ³Office of the Dean, UCSF School of Nursing, San Francisco, USA; ⁴Division of Medical Toxicology, the Icahn School of Medicine at Mount Sinai, New York, USA

11.35  GENERAL DISCUSSION

11.45  Debate: Should RCT be the standard for clinical toxicology?  
Pro: Nick Bateman; Con: Jeffrey Brent

At the end of this session the audience should be able to:
• understand the advantages of a randomized clinical trial in studying treatment of poisoning (Bateman)
• discuss the pros and cons of observational studies in clinical toxicology (Brent)
• discuss the pros and cons of randomized trials in clinical toxicology (Brent)

12.30 ñ 14.00 Lunch and Posters
Symposium: Toxicology in specific populations — Part 2

10.30 Keynote lecture: Bariatric surgery: Implications for clinical toxicology

Marc E Martignoni

Department of Surgery, Klinikum rechts der Isar, Munich, Germany

At the end of this session the audience should be able to:
- describe the indications and procedures in surgery for obese patients
- discuss how surgery in obese patients may influence the diabetic status of the patient
- discuss physiological changes in these patients and how these changes may have an impact in pharmacological/toxicological treatment

10.50 Keynote lecture: Toxicity at therapeutic doses versus acute poisoning: Clinical and pathophysiological differences

Florian Eyer

Department of Toxicology, Klinikum rechts der Isar, Munich, Germany

At the end of this session the audience should be able to:
- recognize the principal mechanisms that may lead to toxicity despite treatment at therapeutic doses
- describe examples of typical drugs that are particularly susceptible to develop toxicity under treatment
- summarize the principal methods to prevent and identify adverse drug reactions even under therapeutic doses
- describe typical drug-drug interactions that may lead to toxicity of at least one involved agent

11.10 *Analysis of enquiries about antiretroviral therapy (ART) involving neonates, as reported to the UK National Poisons Information Service (NPIS) (109)

Rebecca ML Waugh1, Muhammad EMO Elam1, Lucy C Peart1, J Allister Vale2, John P Thompson3, Michael Eddleston4, Simon HL Thomas1

1NPIS Newcastle, Newcastle upon Tyne, UK ; 2NPIS Birmingham, Birmingham, UK ; 3NPIS Cardiff, Cardiff, UK ; 4NPIS Edinburgh, Edinburgh, UK

11.20 GENERAL DISCUSSION

*Short poster oral
Mini symposium: Snake poisoning

11.30  Immunological cross-reactivity and pre-clinical neutralisation of European viper venoms with ViperaTAb antivenom (8)

Nicholas R Casewell, Ibrahim Al-Abdulla, David Smith, Ruth Coxon, John Landon
MicroPharm Limited, Newcastle Emlyn, UK

11.45  Australian elapid envenoming and intracranial haemorrhage (9)

Ingrid Berlin¹, Simon GA Brown², Ferdi Miteff³, Christopher Levi³, Geoffrey K Isbister¹
¹School of Medicine and Public Health, University of Newcastle, Newcastle, Australia; ²Centre for Clinical Research in Emergency Medicine, University of Western Australia, Perth, Australia; ³Department of Neurology, John Hunter Hospital, Newcastle, Australia

12.00  *A multicentre cohort study of snake envenoming defines clinical syndromes and influences clinical practice (95)

Geoffrey K Isbister¹,², Nicholas A Buckley², Colin B Page¹,³, Simon GA Brown⁴
¹School of Medicine and Public Health, University of Newcastle, Newcastle, Australia; ²Clinical Pharmacology, Sydney Medical School, Sydney, Australia; ³School of Medicine, University of Queensland, Brisbane, Australia; ⁴Centre for Clinical Research in Emergency Medicine, University of Western Australia, Perth, Australia

12.10  *Viper envenomation in Italy: Clinical course, laboratory investigations and antivenom treatment in a case series (2002–2012) from Pavia Poison Centre (97)

Andrea Giampreti, Gianluca Melatini, Davide Lonati, Sarah Vecchio, Valeria M Petrolini, Francesca Chiara, Monica Aloise, Marta Crevani, Carlo A Locatelli
Poison Control Centre and National Toxicology Information Centre, Toxicology Unit, IRCCS Maugeri Foundation, Pavia, Italy

12.20  GENERAL DISCUSSION

12.30 î 14.00 Lunch and Posters

*Short poster oral
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>LOUIS ROCHE LECTURE&lt;br&gt;Using routinely collected data to improve visibility and add value to the work of poisons centres in Europe</td>
<td>Simon HL Thomas&lt;br&gt;&lt;br&gt;NPIS, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK</td>
<td>At the end of this session the audience should be able to:&lt;br&gt;• explain the public health value of data collected routinely by poisons centres&lt;br&gt;• describe methods for the effective dissemination of poisons centre data&lt;br&gt;• give examples where the use of poisons centre data has had a beneficial public health impact&lt;br&gt;• predict emerging opportunities for the effective use of poisons centre data in Europe</td>
</tr>
<tr>
<td>15.00</td>
<td>Keynote lecture: Veterinary toxicology: Critical care, lipid therapy and dialysis</td>
<td>Sophie E Adamantos&lt;br&gt;&lt;br&gt;Langford Veterinary Services, University of Bristol, Bristol, UK</td>
<td>At the end of this session the audience should be able to:&lt;br&gt;• describe the common toxins in dogs and cats amenable to lipid therapy&lt;br&gt;• describe the common toxins in dogs and cats that may benefit from advanced therapies such as renal support therapies&lt;br&gt;• describe the limitations of intensive care therapies in dogs and cats compared with people</td>
</tr>
<tr>
<td>15.20</td>
<td>Keynote lecture: Development of a new antivenom against Vipera species for use in canines throughout Europe (10)</td>
<td>Fiona MS Bolton, Nicholas R Casewell, Ibrahim Al-Abdulla, John Landon&lt;br&gt;&lt;br&gt;MicroPharm Ltd, Newcastle Emlyn, UK</td>
<td>At the end of this session the audience should be able to:&lt;br&gt;• recognize the need for the development of a dedicated veterinary antivenom in Europe&lt;br&gt;• describe the properties of the ideal antivenom and the methods used to demonstrate them&lt;br&gt;• describe how these criteria were fulfilled during the development of ViperaVet</td>
</tr>
</tbody>
</table>

**Symposium: Veterinary toxicology**

**15.00**  
**Keynote lecture: Veterinary toxicology: Critical care, lipid therapy and dialysis**  
Sophie E Adamantos  
Langford Veterinary Services, University of Bristol, Bristol, UK

At the end of this session the audience should be able to:
- describe the common toxins in dogs and cats amenable to lipid therapy
- describe the common toxins in dogs and cats that may benefit from advanced therapies such as renal support therapies
- describe the limitations of intensive care therapies in dogs and cats compared with people

**15.20**  
**Keynote lecture: Development of a new antivenom against Vipera species for use in canines throughout Europe (10)**  
Fiona MS Bolton, Nicholas R Casewell, Ibrahim Al-Abdulla, John Landon  
MicroPharm Ltd, Newcastle Emlyn, UK

At the end of this session the audience should be able to:
- recognize the need for the development of a dedicated veterinary antivenom in Europe
- describe the properties of the ideal antivenom and the methods used to demonstrate them
- describe how these criteria were fulfilled during the development of ViperaVet

**15.40 – 16.10 Coffee and Posters**
Symposium: Antidote availability and toxicity

15.00  Keynote lecture: Antidotes: Urgency, efficacy and availability

Ana Ferrer Dufol
Unit of Clinical Toxicology, Clinic University Hospital, Zaragoza, Spain

At the end of this session the audience should be able to:
- discuss the main mechanisms of action of antidotes
- discuss the link between epidemiology of poisoning, urgency of antidote application, antidote effect and availability needs in different health care facilities
- explain how internet tools may be used to set up an efficient antidote network

15.20  Keynote lecture: A National Serum Depot for antivenoms: The set-up and lessons learned (11)

Marieke A Dijkman¹, Bianca Van den Hurk², Irma De Vries¹
¹National Poisons Information Center, University Medical Center, Utrecht, The Netherlands;
²National Institute for Public Health and the Environment, Bilthoven, The Netherlands
Federal Institute for Risk Assessment, Berlin, Germany

At the end of this session the audience should be able to:
- describe the operational structure of an Antivenom Depot organization
- describe how the content of an Antivenom Depot is determined
- discuss the costs involved in establishing and maintaining an Antivenom Depot

15.40  16.10 Coffee and Posters
Symposium: Veterinary toxicology Part 2

16.10 Keynote lecture: Beneficial liaison between poisons centres and veterinary associations
Sophie E Adamantos
Langford Veterinary Services, University of Bristol, Langford, UK

At the end of this session the audience should be able to:
- recognize the benefits of the concept of One Health in identifying common themes between veterinary and human toxicology
- recognize the specific areas of veterinary expertise that may be able to support poison centres
- recognize the similarities and differences between the risk factors and presentation of poisoning in different species

16.30 Keynote lecture: Species and breed predisposition to toxicants in veterinary toxicology
Alexander Campbell
National Poisons Information Service (Birmingham Unit), City Hospital, Birmingham, UK

At the end of this session the audience should be able to:
- discuss the physiological and pharmacological basis for variations in toxicity between species and breed in veterinary toxicology
- list some common examples of species and breed variation in toxicity encountered in veterinary medicine
- identify strategies for ensuring appropriate breed- and species-specific guidance is developed and provided for veterinary users of poisons centres

16.50 Keynote lecture: What's new in US animal poisons?
Tina A Wismer
ASPCA Animal Poison Control Center, Urbana, USA

At the end of this session the audience should be able to:
- discuss trends seen in the managing of animal toxicoses in the US
- discuss changes in rodenticide poisoning in the US secondary to changes in federal regulations
- discuss changes in the severity and occurrence of marijuana intoxication in pets secondary to state legalization and changing attitudes

17.10 GENERAL DISCUSSION

17.30 CLOSE
Symposium: Antidote availability and toxicity – Part 2

16.10 Fomepizole versus ethanol in acute methanol poisoning: A quasi-case-control study (12)
Sergey Zakharov¹, Tomas Navratil¹,², Daniela Pelcova¹
¹Toxicological Information Center, General University Hospital and First Faculty of Medicine of Charles University, Prague, Czech Republic; ²Department of Biophysical Chemistry, J. Heyrovský Institute of Physical Chemistry of the AS CR, v.v.i., Prague, Czech Republic

16.30 Clinical findings in patients receiving physostigmine in a toxicologic ICU: A quality and safety assessment study (13)
Stefan Poechacke¹,², Nina Grossmann¹,², Eva Klingbacher¹,², Burkhard Gustorff²
¹Toxicologic ICU, Wilhelminenspital, Wien, Austria; ²Department of Anesthesiology, Intensive Care and Pain Medicine, Wilhelminenspital, Wien, Austria

16.45 Population pharmacokinetics of an Indian F(ab')2 snake antivenom in patients with Russell's viper bite (14)
Geoffrey K Isbister¹,², Kalana Maduwage¹,², Ana Saião¹, Nicholas A Buckley²,³, Shaluka F Jayamanne²,³, Shahmy Seyed², Fahim Mohamed², Alexandre Mendes⁵, Chandana Abeysinghe², Harindra Karunathilake², Indika Gawarammana², David G Laloo⁶, Janaka H de Silva²,³
¹School of Medicine and Public Health, University of Newcastle, Newcastle, Australia; ²South Asian Clinical Toxicology Research Collaboration, University of Peradeniya, Peradeniya, Sri Lanka; ³Clinical Pharmacology, Sydney Medical School, Sydney, Australia; ⁴Department of Medicine, University of Kelaniya, Ragama, Sri Lanka; ⁵School of Electrical Engineering and Computer Science, University of Newcastle, Newcastle, Australia; ⁶Clinical Sciences and International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK

17.00 The use of digoxin-specific antibodies in chronic digoxin poisoning (15)
Betty S Chan¹,²,³, Margaret O'Leary², Geoffrey Isbister²,³, Nicholas A Buckley²,³
¹Clinical Toxicology Unit & Emergency Department, Prince of Wales Hospital, Sydney, Australia; ²School of Medicine and Public Health, University of Newcastle, Newcastle, Australia; ³Clinical Pharmacology, University of Sydney, Sydney, Australia; ⁴New South Wales Poisons Information Centre, Sydney, Australia

17.15 GENERAL DISCUSSION

17.30 CLOSE
Symposium: Critical care in poisonings

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09.00 | **PLENARY LECTURE**<br>Uncommon indications for extracorporeal removal of toxins (129)  
Robert S Hoffman  
*Division of Medical Toxicology, NYU School of Medicine, New York, USA*  
At the end of this session the audience should be able to:  
• describe the parameters used to evaluate the potential for an unknown or uncommon poison to be removed by extracorporeal therapies  
• explain how to best evaluate the role of extracorporeal therapy in an new or uncommon poisoning  
• discuss the role of extracorporeal toxin removal in hepatotoxic mushroom poisoning, fluoride overdose, manganese toxicity and caffeine poisoning |
| 09.45 | **Keynote lecture: Poison-induced hyperthermic syndromes: Mechanisms and management**  
Philippe Hantson  
*Université catholique de Louvain, Cliniques St Luc, Brussels, Belgium*  
At the end of this session the audience should be able to:  
• discriminate between the mechanisms leading to drug-induced hyperthermia  
• recognize severity criteria of malignant hyperthermia  
• propose therapeutic strategies for drug-induced life-threatening hyperthermia |
| 10.05 | **Keynote lecture: Refractoriness of drug-induced hypotension: Prediction and management (130)**  
Bruno Mégarbane  
*Medical and Toxicological Critical Care Department, Lariboisière Hospital, INSERM U1144 at Paris-Diderot University, Paris, France*  
At the end of this session the audience should be able to:  
• discuss how to determine the exact mechanisms of toxic cardiovascular failure  
• discuss how to predict and identify refractoriness to pharmacological treatments of toxic cardiovascular failure  
• describe the aims of ECMO to treat toxin-induced refractory cardiogenic shock |
| 10.25 | **GENERAL DISCUSSION** |

10.30 ‾ 11.00 Coffee and Posters
Symposium: Utility of experimental data in poisons information and patient management

09.50 Keynote lecture: New approaches to using mechanistic toxicology data in human health risk assessment

*Swiss Centre for Applied Human Toxicology, University of Basel, Basel, Switzerland*

Martin F Wilks

At the end of this session the audience should be able to:

- explain the current paradigm shift in safety testing away from standard animal experiments towards understanding of toxicity pathways in the context of human exposure
- recognize the differences between mechanism of action, mode of action and adverse outcome pathways and their uses in risk assessment
- describe how emerging concepts such as systems toxicology and the human exposome will change the face of health risk assessment

10.10 Keynote lecture: Translation of toxicological findings from lung cell culture models in clinical toxicology

*Institut für Pharmakologie und Toxikologie der Bundeswehr, München, Germany*

Dirk Steinritz

At the end of this session the audience should be able to:

- discuss existing in vitro lung cell culture models and their use in toxicological and pharmacological experiments
- discuss the advantages but also limitations of these models with regard to the experimental data derived thereof
- discuss ongoing research to improve existing models and techniques in order to meet regulatory requirements

10.30 – 11.00 Coffee and Posters
Symposium: Critical care in poisonings - Part 2

11.00  Keynote lecture: Long-term outcome of poisoned patients in the ICU: Determinants and prediction (131)  
Dylan W de Lange  
National Poison Information Center, University Medical Center, Utrecht, The Netherlands

At the end of this session the audience should be able to:
- recognize that, despite good short-term or hospital outcomes, the long-term outcome of poisoned patients is bad
- recognize that the self-reported health-related quality of life (HRQoL) of surviving patients is poor
- recognize that poisoned patients need better follow up and possibly better care if they have been admitted to the ICU

11.20  Keynote lecture: Management of antidotes during extra-renal therapies  
Régis Bédry  
Hospital Secured Unit, Pellegrin University Hospital, Bordeaux, France

At the end of this session the audience should be able to:
- name the antidotes that have to be used during extra-renal therapies compared to those which can be stopped during these techniques
- describe for each antidote their pharmacokinetic profile during extra-renal therapies and the consequences of their use
- describe the practical rules for using antidotes during extra-renal therapies

11.40  Keynote lecture: Drug-induced delirium: Features and management  
Knut Erik Hovda  
The Norwegian CBRNe Centre of Medicine, Oslo University Hospital, Oslo, Norway

At the end of this session the audience should be able to:
- explain the typical features of drug-induced delirium
- describe a strategy for management of drug-induced delirium
- describe features that will commonly increase the susceptibility for drug-induced delirium

12.00  A comparison of vasopressor utility for drug overdose-induced shock (132)  
Dalton Cox¹, Robert S Hoffman², Barry Stimmel³, David Vlahov⁴, Alex F Manini⁵  
¹Emergency Medicine Residency, the Icahn School of Medicine at Mount Sinai, New York, USA; ²Division of Medical Toxicology, NYU School of Medicine, New York, USA; ³Cardiology Division, the Icahn School of Medicine at Mount Sinai, New York, USA; ⁴Office of the Dean, UCSF School of Nursing, San Francisco, USA; ⁵Division of Medical Toxicology, the Icahn School of Medicine at Mount Sinai, New York, USA

12.15  GENERAL DISCUSSION

12.30 ÷ 14.00 Lunch and Posters
Symposium: Utility of experimental data in poisons information and patient management ñ Part 2

11.00 Keynote lecture: Targeted approaches in planning of animal studies on organophosphorus compound poisoning to provide valid information for improved therapy

Horst Thiermann
Institut für Pharmakologie und Toxikologie der Bundeswehr, München, Germany

At the end of this session the audience should be able to:
• discuss similarities and differences with regard to metabolizing enzymes, toxicokinetics of poisons and pharmacokinetics of antidotes in various species
• describe the species dependent oxime-induced reactivation of organophosphorus compounds inhibited acetylcholinesterase
• recognize that oxime efficacy and oxime toxicity are different aspects that both have to be considered when extrapolating animal data to human therapy

11.20 Keynote lecture: The central nervous system in poisoning: What can we learn from animal studies?

Pål Aas
Protection and Societal Security Division, Norwegian Defence Research Establishment (FFI), Kjeller, Norway

At the end of this session the audience should be able to:
• discuss the medical treatment of organophosphate poisoning and understand the requirement for several drugs acting at multiple targets
• describe biomedical research using animal models and understand the specific neuropharmacological approaches
• list the neuronal target areas and critical receptors that can be identified through lesion studies and microinfusion studies, respectively

11.40 Keynote lecture: The liver in poisoning. What can we learn from animal models?

Stephan Krähenbühl
Department of Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

At the end of this session the audience should be able to:
• list the main causes of acute intoxications affecting the liver and name examples
• explain the difference in the suitability of animal models for idiosyncratic and intrinsic toxicants
• explain why animal models for acute liver toxicity are useful for exploring molecular mechanisms of, and susceptibility factors for, toxicity and for testing new experimental therapies

12.00 Keynote lecture: The cardiovascular system in poisoning: What can we learn from animal studies?

Sophie Gosselin
Department of Medicine, McGill University, Montreal, Canada

At the end of this session the audience should be able to:
• discuss possible differences in ADME of a toxin between animals and humans
• discuss differences in cardiovascular responses between various animal species and humans
• discuss challenges in generalizing animal models of poisoning to human overdoses

12.20 GENERAL DISCUSSION

12.30 ñ 14.00 Lunch and Posters
Symposium: Critical care in poisonings † Part 3

14.00  *How to evaluate the severity of lithium-poisoned patients admitted to the intensive care unit? (149)
Dominique Vodovar1, Emmanuel Curis2, Souleiman Elbalkhi2,3, Bruno Mégarbane1,2
1Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris-Diderot University, Paris, France; 2INSERM U1144, Paris-Descartes University, Paris, France; 3Laboratory of Toxicology, Lariboisière Hospital, Paris, France

14.10  *Intoxicated ICU patients: Not only high long-term mortality but also high risk for a low quality of life (143)
Raya Brandenburg1,3, Ivo W Soliman1, Jan Meulenbelt1,3,4, Dylan W de Lange1,2,3
1Department of Intensive Care Medicine, University Medical Center Utrecht, The Netherlands; 2National Intensive Care Evaluation Foundation, Amsterdam, The Netherlands; 3Dutch National Poisons Information Center, University Medical Center Utrecht, The Netherlands; 4Institute for Risk Assessment Sciences, University of Utrecht, The Netherlands

14.20  *Rapid cooling via ice water submersion for severe drug-induced hyperthermia (137)
Larissa K Laskowski, Adaira Landry, Susi U Vassallo, Robert S Hoffman
Department of Emergency Medicine at New York University School of Medicine, Bellevue Hospital Center, New York, USA

14.30  *Multiple intensive care admissions associated with analytically confirmed recreational use of phenibut (β-phenyl-γ-amniobutyric acid) purchased over the Internet (148)
Anselm Wong1, Mark Little2, David Caldicott3, Chris Easton4, Daniel Andres5, Shaun L Greene1
1Victorian Poisons Information Centre and Emergency Department, Austin Hospital, Victoria, Australia; 2Cairns Base Hospital, Queensland, Australia; 3Emergency Department, Calvary Hospital, Canberra, Australia; 4Research School of Chemistry, Australia National University, Canberra, Australia; 5ACT Government Analytical Laboratory, Canberra, Australia

14.40  *Air transport of a severe salicylate intoxicated patient: Unforeseen risks (142)
Rita G McKeever, Gregory S LaSala, David Vearrier, Michael I Greenberg
Division of Medical Toxicology, Drexel University College of Medicine, Philadelphia, USA

14.50  GENERAL DISCUSSION

14.55  Debate: Should magnesium be systematically used in QT prolongation to prevent torsade de pointe?
Pro: Jonas Höjer; Con: Donna Seger

At the end of this session the audience should be able to:
• describe how the heart rate affects the risk for torsade de pointes in a poisoned patient with a QTc time of more than 500 ms (Höjer)
• discuss the role magnesium plays in TdP and the lack of value in prophylactic treatment of TdP (Seger)

15.40 † 16.10 Coffee and Posters

*Short poster oral
Mini symposium: Occupational and Environmental exposures

14.00  Markers of oxidative stress and inflammation are more elevated in the exhaled breath condensate of workers exposed to nano-TiO2 than to nano-Fe oxide particles (135)
   Daniela Pelclova¹, Sergej Zacharov¹, Vladimir Zdimal², Zdenka Fenclova¹, Stepanka Vlckova¹, Kamila Syslova¹, Marek Kuzma³, Tomas Navratil³, Martin Komer⁴, Petr Kacer⁴
   ¹Department of Occupational Medicine, Charles University and General University Hospital, Prague, Czech Republic; ²Institute of Chemical Process Fundamentals, AS CR, v.v.i., Prague, Czech Republic; ³Institute of Chemical Technology, AS CR, v.v.i., Prague, Czech Republic; ⁴Institute of Microbiology, AS CR, v.v.i., Prague, Czech Republic; ⁵J. Heyrovsky Institute of Physical Chemistry, AS CR, v.v.i., Prague, Czech Republic; ⁶Institute of Informatics, Charles University and General University Hospital, Prague, Czech Republic

14.15  Relationship between long-term exposure to ambient air pollution, blood pressure and inflammatory processes among young subjects (136)
   Iwona Gawlik, Jakub Marchewka, Krzysztof Bryniarski, Grzegorz Debski, Rafal Badacz, Ida Marchewka, Jakub Konieczynski, Natalia Podolec, Anna Zabowka, Tomasz Guzik
   Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland

   Jolene Okaneku, Rita McKeever, David Vearrier, Michael I Greenberg
   Department of Emergency Medicine, Drexel University College of Medicine, Philadelphia, USA

14.40  *Serious magic-nano-like lung oedemas caused by a liquid stain protection product: Using two new tests as a combined screening tool for aerosol products (181)
   Axel Hahn¹, Monika Fischer², Dorothee Walter², Clemens Dasenbrock², Wolfgang Koch², Kathrin Begemann³, Matthias Greiner⁴
   ¹Federal Institute for Risk Assessment (BfR), Berlin, Germany; ²Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany

*Short poster oral
Mini symposium: Occupational and Environmental exposures

14.50  *Evaluation of clinical effects after high pressure injection injuries of the hand using 20 years experience of Pavia Poison Centre: A toxicological and surgical emergency (258)*

Francesca Chiara, Davide Lonati, Andrea Giampreti, Valeria M Petrolini, Sarah Vecchio, Carlo A Locatelli

Poison Control Centre and National Toxicology Information Centre, Toxicology Unit, IRCCS Maugeri Foundation, Pavia, Italy

15.00  *Carbon monoxide poisoning: Comparison between French and German monitoring systems (186)*

Christine Tournoud1, Uwe Stedtler2, Laurent Berthelon1, Maren Hermanns-Clausen2, Ingrid Blanc3, Françoise Flesch1

1Poison and Toxicovigilance Centre, University Hospitals, Strasbourg, France; 2Poisons Information Centre, Children’s University Hospital, Freiburg, Germany; 3Poison and Toxicovigilance Centre, Fernand Widal Hospital, Paris, France

15.10  *Acute pulmonary injuries from chlorine-based swimming pool disinfectants in northern Germany (175)*

Martin Ebbecke, Rafael Wagner, Herbert Desel, Andreas Schaper

GIZ-Nord Poisons Centre, University Medical Center, Göttingen, Germany

15.20  GENERAL DISCUSSION

15.30 ÷ 16.10 Coffee and Posters

*Short poster oral
Mini symposium: Chemical poisoning: Challenges and Surveillance Methods

16.10  Chemical and biological terrorist attacks identified through the Global Terrorism Database (133)
        J Priyanka Vakkalanka, Jennifer L Parker Cote, Rachel Schwartz, Joshua D King, Nathan P
        Charlton, Christopher P Holstege
        Blue Ridge Poison Center, University of Virginia School of Medicine, Charlottesville, USA

16.25  Surveillance of hazardous exposures to liquid laundry detergent capsules in Italy: A
        preliminary evaluation of the impact of preventive measures (134)
        Franca Davanzo¹, Laura Settimi², Anna Celentano¹, Felice Giordano³, Laura Lauria²,
        Leonardo Molino¹, Maria Laura Zuccoli¹, Beatrice Gilotti¹, Fabrizio Sesana¹
        ¹National Poison Control Center in Milan, Ospedale Niguarda Cà, Milan, Italy; ²National
        Institute of Health (ISS), Rome, Italy; ³La Sapienza University, Rome, Italy
Mini symposium: Chemical poisoning: Challenges and Surveillance Methods

16.40 *The European Chemical Emergency Network (ECHEMNET): An EU-level network of experts to respond to cross-border chemical incidents (191)

Charlotte V Hague¹, Rob Orford¹, Herbert Desel², Andreas Schaper², Lisbeth Hall³, Sally Hoffer³, Ann Goransson Nyberg³, Per Leffler⁴, Elisabeth Wigenstam⁴, Agneta Plamboeck⁵, Jiri Trnka⁴, María del Carmen García Cazalilla⁵, Jesus Ocaña García-Donas⁵, Jose Javier García del Aguila⁵, Raquel Duarte-Davidson¹

¹Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton, UK; ²GIZ-Nord Poisons Centre, University Medical Center Göttingen, Göttingen, Germany; ³National Institute for Public Health and the Environment (RIVM), Advisory Service for the Inspectorate Environment, Bilthoven, The Netherlands; ⁴Swedish Defence Research Agency (FOI), CBRN Defence and Security, Umeå, Sweden; ⁵Empresa Pública de Emergencias Sanitarias (EPES), Healthcare Delivery Management Dept, Malaga, Spain

16.50 *Fear of secondary exposure of healthcare personnel can lead to disproportionate measures (195)

Ronald de Groot¹, Antoinette JHP van Riel¹, Gerard A van Zoelen¹, Marianne EC Leenders¹,², Irma de Vries¹, Jan Meulenbelt¹,³

¹National Poisons Information Center, University Medical Center, Utrecht, The Netherlands; ²Department of Anesthesiology, University Medical Center, Utrecht, The Netherlands; ³Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands

17.00 Close

17.15 ï 18.15 EAPCCT GENERAL ASSEMBLY (Auditorium II)

*Short poster oral
Thursday 28 May 2015

Auditorium II

Poster discussion session
(10 posters selected for short oral presentation)

16.10 Poster presentation and discussion ï to be confirmed
16.15 Poster presentation and discussion ï to be confirmed
16.20 Poster presentation and discussion ï to be confirmed
16.25 Poster presentation and discussion ï to be confirmed
16.30 Poster presentation and discussion ï to be confirmed
16.35 Poster presentation and discussion ï to be confirmed
16.40 Poster presentation and discussion ï to be confirmed
16.45 Poster presentation and discussion ï to be confirmed
16.50 Poster presentation and discussion ï to be confirmed
16.55 Poster presentation and discussion ï to be confirmed
17.00 Close

17.15 ñ 18.15 EAPCCT GENERAL ASSEMBLY
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Introduction to Young Investigator Award</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.35</td>
<td>Indian Krait (Bungarus caeruleus) envenoming: A clinical and neurophysiological investigation of neuromuscular dysfunction (261)</td>
<td>Anjana Silva&lt;sup&gt;1,2&lt;/sup&gt;, Sisira Siribaddana&lt;sup&gt;2&lt;/sup&gt;, E Michael Sedgwick&lt;sup&gt;3&lt;/sup&gt;, Kalana Maduwage&lt;sup&gt;4&lt;/sup&gt;, Nicholas Buckley&lt;sup&gt;3&lt;/sup&gt;, Geoffrey K Isbister&lt;sup&gt;4&lt;/sup&gt;</td>
<td>&lt;sup&gt;1&lt;/sup&gt;Monash Venom Group, Monash University, Melbourne, Australia; &lt;sup&gt;2&lt;/sup&gt;Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Sri Lanka; &lt;sup&gt;3&lt;/sup&gt;South Asian Clinical Toxicology Research Collaboration, University of Peradeniya, Peradeniya, Sri Lanka; &lt;sup&gt;4&lt;/sup&gt;School of Medicine and Public Health, University of Newcastle, Newcastle, Australia</td>
</tr>
<tr>
<td>08.50</td>
<td>External validation of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity from paracetamol overdose (262)</td>
<td>Anselm Wong&lt;sup&gt;1&lt;/sup&gt;, Marco L Sivilotti&lt;sup&gt;2&lt;/sup&gt;, Paul I Dargan&lt;sup&gt;3&lt;/sup&gt;, David M Wood&lt;sup&gt;3&lt;/sup&gt;, Shaun L Greene&lt;sup&gt;1&lt;/sup&gt;</td>
<td>&lt;sup&gt;1&lt;/sup&gt;Victorian Poisons Information Centre and Emergency Department, Austin Hospital, Victoria, Australia; &lt;sup&gt;2&lt;/sup&gt;Emergency Medicine, Pharmacology and Toxicology, Queen's University, Kingston, Canada.; &lt;sup&gt;3&lt;/sup&gt;Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and Kings Health Partners, London, UK</td>
</tr>
<tr>
<td>09.05</td>
<td>Do benzodiazepines worsen tramadol toxicity? An experimental study in the rat (263)</td>
<td>Camille Lagard&lt;sup&gt;1&lt;/sup&gt;, Lucie Chevillard&lt;sup&gt;1&lt;/sup&gt;, Isabelle Malissin, Patricia Riséde&lt;sup&gt;1&lt;/sup&gt;, Jacques Callebert&lt;sup&gt;1&lt;/sup&gt;, Laurence Labat&lt;sup&gt;1&lt;/sup&gt;, Bruno Mégarbane&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>&lt;sup&gt;1&lt;/sup&gt;INSERM U1144, Paris- Descartes University, Paris, France; &lt;sup&gt;2&lt;/sup&gt;Department of Medical and Toxicological Critical Care Medicine, Lariboisière Hospital, Paris, France</td>
</tr>
<tr>
<td>09.20</td>
<td>The myth of the half RR rule and QT prolongation (264)</td>
<td>Ingrid Berling&lt;sup&gt;1,2&lt;/sup&gt;, Geoffrey K Isbister&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>&lt;sup&gt;1&lt;/sup&gt;Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, Newcastle, Australia; &lt;sup&gt;2&lt;/sup&gt;School of Medicine and Public Health, University of Newcastle, Newcastle, Australia</td>
</tr>
<tr>
<td>09.35</td>
<td>Judging commences</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.35</td>
<td>Keynote lecture: Toxicology: from St Paul to the Movies and beyond; a Maltese perspective</td>
<td></td>
<td>Mark Zammit</td>
</tr>
<tr>
<td>09.55</td>
<td>Presentation to the winner of the Young Investigator Award</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

10.00 ÷ 10.30 Coffee and Posters
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>YOUNG INVESTIGATOR AWARD (Auditorium I)</td>
</tr>
<tr>
<td>10.00</td>
<td>and Keynote lecture: Toxicology: from St Paul to the Movies and beyond; a Maltese perspective</td>
</tr>
</tbody>
</table>

10.00 – 10.30 Coffee and Posters
Symposium: Drugs of misuse

10.30  Keynote lecture: Gamma-hydroxybutyrate (GHB) and related analogue dependency and withdrawal

David Wood

Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK

At the end of this session the audience should be able to:
• recognize the pattern of use of GHB and related analogues that is associated with dependency and risk of withdrawal
• describe the clinical features of GHB and related analogue withdrawal
• outline the management of planned and unplanned GHB and related analogue withdrawal

10.50  Keynote lecture: Naloxone public availability and use

Lewis S Nelson

Department of Emergency Medicine, NYU Langone Medical Center, New York, USA

At the end of this session the audience should be able to:
• describe the mechanism to provide naloxone for administration by non-medical personnel
• list several benefits of expanding the public availability of naloxone for such use
• discuss several risks of naloxone expansion and mechanisms to limit the adverse consequences

11.10 Keynote lecture: The toxicological significance of recreational drug and novel psychoactive substance (NPS) adulterants

Fridtjof Heyerdahl

Dept of Anesthesiology, Oslo University Hospital, Oslo, Norway

At the end of this session the audience should be able to:
• name common adulterants found in recreational drugs and NPS
• discuss the clinical relevance of these adulterants
• recognize clinical situations in which toxicity related to adulterants should be suspected

11.30 Influence of naltrexone induction regime on the stress hormones levels during rapid opioid detoxification (265)

Robertas Badaras¹, Gabija Dragelyte¹, Linas Zdanavicius¹, Tomas Jovaisa², Juozas Ivaskevicius

¹Centre of Toxicology, Vilnius University, Vilnius, Lithuania; ²Clinic of Anaesthesiology, Lithuanian University of Health Sciences, Kaunas, Lithuania; ³Clinic of Anaesthesiology and Intensive Care, Vilnius University, Vilnius, Lithuania
Symposium: Drugs of misuse

11.45 Validation of two different screening ELISA assays for synthetic cathinones (mephedrone/methylcathinone and MDPV) with confirmatory LC-MS in intoxicated patients (266)

   Elisa Roda¹, Davide Lonati¹, Sarah Vecchio¹, Eleonora Buscaglia¹, Pietro Papa², Loretta Rocchi², Carlo A Locatelli¹, Teresa Coccini¹

   ¹Laboratory of Clinical & Experimental Toxicology and Poison Control Center, IRCCS Maugeri Foundation, Pavia, Italy; ²Laboratory of Analytical Toxicology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

12.00 The cathinones are the most commonly reported Novel Psychoactive Substances (NPS) associated with Emergency Department presentations with acute drug toxicity reported to the European Drug Emergencies Network (Euro-DEN) (267)

   David M Wood¹, Alison M Dines¹, Fridtjof Heyerdahl², Christopher Yates³, Isabelle Giraudon⁴, Knut Erik Hovda⁵, Paul I Dargan¹, on behalf of the Euro-DEN Research Group

   ¹Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London, UK; ²Norwegian National Unit for CBRNe Medicine, Oslo University Hospital, Oslo, Norway; ³Emergency Department and Clinical Toxicology Unit, Hospital Universitari Son Espases, Mallorca, Spain; ⁴European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal

12.15 Monoamine transporter and receptor interaction profiles of psychoactive benzofurans (268)

   Anna Rickli¹, Simone Kopf¹, Marius C Hoener², Matthias E Liechti¹

   ¹Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland; ²Neuroscience Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland

12.30 – 14.00 Lunch and Posters
The best papers of 2014 or papers you may have missed

10.30 The best papers of 2014 or papers you may have missed

An international panel will each be asked to select a clinical toxicology paper published in the year 2014 that they consider to be among the best. The aim is to highlight papers that have changed or challenged clinical practice, taught something new or unexpected, improved understanding of toxicological mechanisms, or inspired the panellists. Three speakers, from different countries, will defend their choice in a brief 10 minute presentation followed by discussion.

Discussants:

Lotte Hoegberg

Allister Vale

Geert Verstegen
## Round table: Training in Poison Centres

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Round table: Training in Poison Centres</td>
</tr>
<tr>
<td></td>
<td><strong>Pre-employment education for poisons information staff</strong></td>
</tr>
<tr>
<td></td>
<td>John Thompson</td>
</tr>
<tr>
<td></td>
<td><em>National Poisons Information Service, Cardiff, UK</em></td>
</tr>
<tr>
<td></td>
<td><strong>Initial and ongoing education for poisons centre staff† A European perspective</strong></td>
</tr>
<tr>
<td></td>
<td>Hugo Kupferschmidt</td>
</tr>
<tr>
<td></td>
<td><em>Tox Info Suisse, Zurich, Switzerland</em></td>
</tr>
<tr>
<td></td>
<td><strong>Initial and ongoing education for poisons centre staff† A North-American perspective</strong></td>
</tr>
<tr>
<td></td>
<td>Jay Schauben</td>
</tr>
<tr>
<td></td>
<td><em>American Association of Poison Control Centers, Jacksonville, USA</em></td>
</tr>
<tr>
<td></td>
<td><strong>Specific training and educational needs of different staff groups</strong></td>
</tr>
<tr>
<td></td>
<td>Lotte Høgberg</td>
</tr>
<tr>
<td></td>
<td><em>The Danish Poisons Information Centre, Copenhagen Denmark</em></td>
</tr>
<tr>
<td></td>
<td><strong>Moving forward - what educational standards should be met for poisons centre staff† individual accreditation?</strong></td>
</tr>
<tr>
<td></td>
<td>Irma de Vries</td>
</tr>
<tr>
<td></td>
<td><em>Dutch Poisons Information Center, Utrecht, The Netherlands</em></td>
</tr>
<tr>
<td></td>
<td><strong>Followed by 30 minutes panel discussion</strong></td>
</tr>
</tbody>
</table>

- 12.30 † 14.00 *Lunch and Posters*
Symposium: Drugs of misuse - Part 2

14.00  Clinical toxicity of synthetic cannabinoid receptor agonist use (269)
Alex F Manini1, Robert S Hoffman2, Barry Stimmel3, David Vlahov4
1Division of Medical Toxicology, the Icahn School of Medicine at Mount Sinai, New York, USA; 2Division of Medical Toxicology, NYU School of Medicine, New York, USA; 3Cardiology Division, the Icahn School of Medicine at Mount Sinai, New York, USA; 4Office of the Dean, UCSF School of Nursing, San Francisco, USA

14.15  *Do users of novel psychoactive substances take what they think they take? An overview of drug product contents analysed within the Swedish STRIDA project (271)
Matilda Bäckberg1, Erik Lindeman1, Olof Beck2, Karl-Henrik Jönsson3, Anders Helander2
1Swedish Poisons Information Centre, Stockholm, Sweden; 2Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; 3Official Medicines Control Laboratory, Medical Products Agency, Uppsala, Sweden

14.25  *Acute autonomic and psychotropic effects of LSD in healthy subjects in a placebo-controlled study (274)
Yasmin Schmid, Patrick C Dolder, Matthias E Liechti
Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland

14.35  GENERAL DISCUSSION

14.45  Debate: Should cannabis be legalised in terms of public health issues?
Pro: Karen Simone
Con: Rick Dart

At the end of this session the audience should be able to:
- describe how cannabis legalization may address safety concerns associated with unregulated marijuana (Simone)
- describe the characteristics of cannabis use and abuse when it becomes a legal substance (Dart)

15.30 - 16.00 Coffee and Posters

*Short poster oral
Mini symposium: Toxicology of antidiabetic medications

14.00  Keynote lecture: The pharmacology and toxicology of new medications to treat diabetes

George M Bosse1,2
1Department of Emergency Medicine, University of Louisville, USA; 2Kentucky Regional Poison Center, Louisville, USA

At the end of this session the audience should be able to:
- discuss the pharmacology of the GLP-1 analogs, DPP-4 inhibitors, SGLT2 inhibitors and amylin analogs
- discuss the toxicology and clinical experience to date with overdose of these drugs
- discuss management of overdose of these drugs from both a poison center and emergency department standpoint

14.20  Keynote lecture: An update on the management of sulfonylurea toxicity

Yedidia Bentur
Israel Poison Information Center, Rambam Health Care Campus, Haifa, Israel

At the end of this session the audience should be able to:
- explain the mechanisms of action of sulfonylureas and octreotide
- describe the laboratory tests required for diagnosing sulfonylureas as the cause of hypoglycaemia
- implement current recommendations for the use of octreotide in sulfonylurea-induced hypoglycaemia

14.40  Keynote lecture: Metformin toxicity: mechanisms and management

John RH Archer
Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK

At the end of this session the audience should be able to:
- describe the mechanism of action and pharmacokinetics of metformin
- explain how metformin may lead to toxic effects both in therapeutic use and in overdose
- list the main objectives for the treatment of metformin toxicity

15.00  *Prolonged, refractory glyburide and nateglinide toxicity in the setting of acute renal failure (334)

Jennifer C Cabot1, James S Morrison1, Alex F Manin2
1Emergency Medicine Residency, the Icahn School of Medicine at Mount Sinai Hospital, New York, USA; 2Division of Medical Toxicology, the Icahn School of Medicine at Mount Sinai Hospital, New York, USA

*Short poster oral
Mini symposium: Toxicology of antidiabetic medications

15.10 *Mortality predictors in lactic acidosis with confirmed serum metformin concentration (343)
Daniel Morell-García¹, Loreto Quesada Redondo¹, Emilia Civeira Murillo², Isabel Gomila Muñiz¹, Juan Robles Bauzá¹, Andrés Carrillo López³, Jordi Puiguriguerr Ferrando⁴, Ana Ferrer Dufo⁵, Bernardino Barceló Martín¹

¹Servicio de Análisis Clínicos-Unidad de Toxicología Clínica, Hospital Universitari Son Espases, Palma de Mallorca, Spain; ²Unidad de Cuidados Intensivos-Unidad de Toxicología Clínica, Hospital Clínico de Zaragoza, Zaragoza, Spain; ³Unidad de Cuidados Intensivos, Hospital Universitari Son Espases, Palma de Mallorca, Spain; ⁴Servicio de Urgencias Médicas-Unidad de Toxicología Clínica, Hospital Universitari Son Espases, Palma de Mallorca, Spain; ⁵Unidad de Toxicología Clínica, Hospital Clínico de Zaragoza, Zaragoza, Spain

15.20 GENERAL DISCUSSION

15.30 — 16.00 Coffee and Posters

*Short poster oral
### Mini symposium: Medicine abuse

**16.00**  
*Oxycodone/naloxone preparations can cause acute opioid withdrawal symptoms following intravenous and oral exposure (300)*

Anselm Wong¹, Dawson Macleod¹, Jeff Robinson¹, Zeff Koutsogiannis¹, Andis Graudins²,  
Shaun L. Greene¹

¹Victorian Poisons Information Centre and Emergency Department, Austin Hospital, Victoria, Australia; ²Monash Health Clinical Toxicology Service and School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia

**16.10**  
*Estimating nonmedical use of prescription opioids in the United States from social media (301)*

Michael Chary¹, Nick Genes², Christophe Giraud-Carrier³, Carl Hanson⁴, Lewis Nelson⁵, Alex F Manini⁶,⁷

¹Icahn School of Medicine at Mount Sinai, New York, USA; ²Department of Emergency Medicine, Mount Sinai Hospital, New York, USA; ³Department of Computer Science, Brigham Young University, Provo, USA; ⁴Department of Health Science, Brigham Young University, Provo, Utah, USA; ⁵Department of Emergency Medicine, NYU Langone Medical Center, New York, USA; ⁶Division of Medical Toxicology, Icahn School of Medicine at Mount Sinai, New York, USA

**16.20**  
*Dextromethorphan abuse in adolescence: A rising trend (302)*

Blanka Caganova, Silvia Plackova, Petra Faltanova

National Toxicological Information Centre, University Hospital Bratislava, Bratislava, Slovak Republic

**16.30**  
*The rise in prescription parenteral opiate abuse: Cases reported to an Australian Poisons Information Centre (305)*

Nicole E Wright, Rose Cairns, Jared A Brown

NSW Poisons Information Centre, Sydney Children’s Hospital Network, Westmead, Australia

**16.40**  
*Chronic pain and non-medical use of opioids, benzodiazepines and pregabalin in an online national survey in the United Kingdom (311)*

Paul I Dargan¹, David M Wood¹, Andrea C Besharat², Erin M Martinez², Jody L Green²

¹Clinical Toxicology, Guy’s and St. Thomas’ NHS Foundation Trust and King’s Health Partners, London, UK; ²Rocky Mountain Poison & Drug Center, Denver Health, Denver, USA

**16.50**  
*Characterization of acute opioid overdose in the ToxIC Registry (313)*

Katherine L Boyle, Lynn A Farrugia, Jennifer L Carey, on behalf of the ToxIC Consortium

University of Massachusetts Medical School, Worcester, USA

**17.00**  
*Trends over time in population rates of intentional misuse and self-harm mentions with buprenorphine, methadone, and oxycodone as reported to poison centres in Germany, Italy and the United Kingdom (306)*

Becki Bucher Bartelson¹, Herbert Desel², Andreas Schaper², Franca Davanzo³, Fabrizio Sesana³, Gillian Cooper⁴, John P Thompson⁴, Darcey JG Johnson¹, Jody L Green¹

¹Rocky Mountain Poison & Drug Center, Denver Health, Denver, USA; ²GIZ-Nord Poisons Centre, University Medical Center, Göttingen, Germany; ³Poison Control Centre of Milan, Azienda Ospedaliera Ospedale Niguarda Ca’ Granda, Milan, Italy; ⁴National Poisons Information Service, Cardiff, UK

**17.10**  
GENERAL DISCUSSION

**17.25** Close

*Short poster oral*
Poster discussion session  
(15 posters selected for short oral presentation)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation and Discussion</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.05</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.10</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.15</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.20</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.25</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.30</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.35</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.40</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.45</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.50</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>16.55</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>17.00</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>17.05</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>17.10</td>
<td>Poster presentation and discussion</td>
<td>to be confirmed</td>
</tr>
<tr>
<td>17.15</td>
<td>GENERAL DISCUSSION</td>
<td></td>
</tr>
</tbody>
</table>

17.25 Close
Epidemiology of poisoning

16. The antipsychotic story: an epidemic of prescription and overdose
   Ingrid Berling, Nicholas A Buckley, Geoffrey K Isbister

17. Intentional exposures on school property reported to U.S. Poison Centers
   J Priyanka Vakkalanka, Joshua D King, Christopher P Holstege

18. 15 years of Vitamin D exposures reported to US Poison Centers
   Henry A Spiller, Theodore F Good, Alfred Aleguas

19. Nicotine poisoning related to the use of e-cigarettes
   Sara W Lindberg, Niels Ebbehoej, John Bang, Lars B Christensen

20. Acute poisonings in Iceland: Self-poisonings presenting to the Emergency Departments at Landspitali-University Hospital. Comparison between 2001 and 2012
   Gudborg Gudjonsdottir, Jakob Kristinsson, Anna M Thordardottir

   J Craig Nelson, James B Mowry, Daniel A Spyker

22. Analysis of telephone enquiries to the United Kingdom National Poisons Information Service (NPIS) concerning raspberry ketone weight loss supplements (2011-2014)
   Stephen Jones, Alison M Thomas, J Allister Vale, Michael Eddleston, Simon HL Thomas, John P Thompson

23. Intentional overdoses and self-harm enquiries in adolescents aged 8-16: A retrospective review of enquiries to the National Poisons Information Service in the United Kingdom
   Eleri Thomas, Gillian A Cooper, J Allister Vale, Michael Eddleston, Simon HL Thomas, John P Thompson

   Yury N Ostapenko, Soso O Mebonia, Olga V Arepieva

25. Epidemiology of pharmacological poisoning by oral antidiabetic drugs in Morocco
   Narjis Badrane, Fatima Abadi, Ahlam Mefiah, Driss Soussi Tanani, Naima Rhalem, Rachida Soulaimani Bencheikh

26. Periodicity of human exposures in suicidal intention reported to the Poisons Information Centre (PIC) Erfurt from 2004 to 2013
   Helmut Hentschel, Dagmar Prasa, Germaine Frimlova, Simone Just, Gisela Liebetrau, Bettina Plenert, Anne Stuerzebecher, Michael Deters.

   Rachida Aghandous, Naima Rhalem, Lahcen Ouammi, Abdelmajid Soulaimani, Abdelrhani Mokhtari, Rachida Soulaimani-Bencheikh
Antidotes

28. Tolerance and efficacy of a new antivenom Fab2 variety in the treatment of Bothrops lanceolatus bites in Martinique
   Dabor Resiere, Vanessa Chomono, Ruddy Valentino, Cyrille Chabartier, Jeanlouis Ferge, Etienne Caffiot, Stephane Kaidomar, Michel Schoelsser, Yanick Brouste, Victor Moravie, Bruno Megarbane, Hossein Mehdaoui

29. Hydroxocobalamin and sodium thiosulfate in acute cyanide poisoning
   Sergey Zakharov, Pavel Urban, Tomas Navratil, Manuela Vaneckova, Zdenek Seidl, Pavel Diblik, Pavel Kuthan, Daniela Pelclova

30. Pre-hospital ethanol administration improves outcomes in mass methanol outbreaks
   Sergey Zakharov, Daniela Pelclova, Pavel Urban, Tomas Navratil, Pavel Diblik, Ivana Kurcova, Jaromir Belacek, Martin Komar, Michael Eddleston, Knut Erik Hovda

31. Variations in serum ethanol concentrations during the treatment of acute methanol poisoning
   Sergey Zakharov, Tomas Navratil, Tomas Salek, Ivana Kurcova, Daniela Pelclova

32. Fomepizole kinetics during intermittent (IHD) and continuous hemodialysis (CVVHD): A case study
   Knut Erik Hovda, Trond Vartdal, Brian Latimer, Gaut Gadeholt, Kenneth E McMartin, Dag Jacobsen

33. Comparison of adverse drug reaction rates using a two-bag to a standard three-bag intravenous acetylcysteine regimen for paracetamol poisoning
   Andis Graudins, Angela Harper

34. A novel infusion protocol for the administration of acetylcysteine
   Geoffrey K Isbister, Michael A Downes, Kylie McNamara, Ingrid Berling, Ian M Whyte, Colin B Page

35. Is normobaric oxygen efficient in cyanide poisoning? A systematic review of individual cases
   Frederic J Baud, Wilfried Steffens, Stephen W Borrion, Roland Rödelsperger, Ulrike Kuepper, Herlinde Smet, Thomas Zilker, Henk Vrijhof

36. Admission characteristics of patients receiving physostigmine in a Toxicologic ICU: A quality and safety assessment study
   Stefan Poechacker, Nina Grossmann, Eva Klingbacher, Burkhard Gustorff

37. A 2-year analysis of scorpion envenomations in a regional poison center following new scorpion antivenom introduction to the US market
   Shireen Banerji, Alvin Bronstein.

38. Intravenous lipid emulsion for amlodipine/benazepril toxicity: A case report
   Rachel Schult, RM Gorodetsky, TJ Wiegand

39. Successful management of acute collective hydrogen sulfide exposure
   Isabella Orsini, Chiara Pracucci, Primo Botti, Francesco Gambassi, Alessandra Ieri, Emanuela Masini, Guido Mannaioni
40. The impact of new paracetamol treatment guidelines on children who take accidental acute paracetamol overdose
   Emer Timony-Nolan, Elaine Donohoe, Edel Duggan, Ronan O'Sullivan

41. A new national antidote database: An open online service
   Stefan Arvidsson, Mark Personne

42. Chemical instability of glucagon when given as a continuous infusion
   Yvonne Lao, Fridtjof Heyerdahl

43. Doubling the third dose of intravenous N-acetylcysteine survey: An international practice perspective
   Saad Al Juma, Eric Villeneuve, Audree Elliot, Robert B Palmer, Sophie Gosselin

44. Early administration of isosorbide dinitrate improves survival of cyanide-poisoned rabbits
   Ophir Lavon

45. Evolution of the antidote treatment in acute poisoning in an emergency department
   Pilar Miranda-Arto, Ana Ferrer-Dufol, Francisco J Ruiz-Ruiz, Sebastian Menao-Guillen

46. Severe cardio-respiratory adverse effects after concentrated and rapid intravenous fomepizole administration: A case report
   Davide Lonati, Francesca Chiara, Giulia Scaravaggi, Veronica Basso, Luca Chiovato, Carlo A Locatelli

47. Safe and effective use of phystostigmine for olanzapine overdose
   Rachel M Gorodetsky, Rachel Schult, Timothy J Wiegand

48. Antidote treatment of poisoned children before admission to the Toxicology Department
   Viorela Nitescu, Stefan Gatcan, Nicolae Stanciu, Elena Galamaga, Cristina Oglinda, Ana Oglinda

49. Is hyperbaric oxygen efficient in cyanide poisoning? A systematic review of individual cases
   Frederic J Baud, Wilfried Steffens, Stephen W Borron, Roland Roedalsperger, Ulrike Kuepper, Herlinde Smet, Thomas Zilker, Henk Vrijhof

50. N-acetylcysteine treatment of paracetamol poisonings in the Czech Republic and Slovakia: Outcomes and side effects
   Michal Urban, Blanka Caganova, Silvia Plackova, Ivana Kurcova, Sergej Zacharov, Daniela Pelclova

51. First-line sodium thiosulphate effective administration in a case of potassium cyanide suicidal ingestion
   Diletta Sabatini, Andrea Giampreti, Paolo Mazzini, Carla Caranti, Laura Rolandi, Rolando De Sanctis, M Caterina Grassi

52. Massive paracetamol overdose: Early NAC prevented liver damage but not pancytopenia
   Jonas Höjer
53. Severe pediatric cyanide poisoning due to smoke inhalation: Two cases
   Marco Marano, Mara Pisani, Matteo Di Nardo, Corrado Cecchetti, Caterina Tomasello, Paola De Rose, Davide Lonati

54. Antidote availability in emergency departments in the manucipality of Campinas, São Paulo state, Brazil
   Luciane CR Fernandes, Camila C Prado, Maira M Branco, Carla B Fernandes, Eduardo M De Capitani, Stephen Hyslop, Fabio Bucaretti

55. Naloxone availability in the USA: Bystander versus emergency medical services (EMS) administration
   Alberto Perez, Richard A Kamin, Tamas Peredy

56. Comparison of hyperbaric oxygen treatment reported to poison centers in the US and Israel
   Wendy Klein-Schwartz, Yedidia Bentur

**Toxic deaths**

57. Accidental laundry pod exposure resulting in first reported US fatality
   Alfred Aleguas, Tamas R Peredy

58. Mortality after antipsychotic poisoning
   Henrik Horwitz, Kim Dalhoff, Gesche Jürgens

59. Changes in pediatric poisoning mortality: A 20-year retrospective study
   Viorela Nitescu, Dora Boghitoiu, Iuliana Gherlan, Doina Coman, Anca Donoica, Andreea Odagiu, Catalin Stemate, Coriolan Ulmeanu

60. Causality assessment of fatal poisoning: Evaluation of the GfkT causality score
   Maren Hermanns-Clausen, Andreas Schaper, Angelika Holzer, Ingrid Koch, Andreas Stürer, Anne Stürzebecher, Stephan Rhode, Hugo Kupferschmidt

61. Poisoning deaths in Poland: Type and prevalence detected on analysis of cases from 6 poison centres during the period 2009-2013
   Anna Krakowiak, Anna Piekarska-Wijatkowska, Piotr Hydzik, Beata Szkolnicka, Tomasz Kępotowski, Sebastian Picheta, Barbara Porębska, Andrzej Antoś, Daria Schetz, Jacek Sein Anand, Magda Gąsiski-Ogłońska, Paulina Pastuszka

62. In-hospital mortality after toxic exposures in Spain, the EXITOX project
   Jordi Puiguriguerr Ferrando, Ana Ferrer Dufol, Santiago Nogué Xarau

63. Toxicologic related deaths: A case series from 1970 to 2014
   Francesco Gambassi, Primo Botti, Alessandra Ieri, Chiara Pracucci, Lara Bertieri, Guido Mannaioni
64. Characteristics of deaths in subjects with post-mortem detection of cannabis: Preliminary results
Sophie Garapon, Nathalie Grosleron-Gros, Véronique Dumestre, Régis Bédry, Jean Hiquet, Emilie Christin, Sophie Gromb-Monnoyeur

65. Once upon a time the toxic related deaths: A case series from 1924 to 1960
Francesco Gambassi, Primo Botti, Alessandra Ieri, Chiara Pracucci, Lara Bertieri, Andrea Misanelli, Isabella Orsini, Guido Mannaioni, Emanuela Masini

66. Fatal poisonings in Estonia 2002-2013
Raido Paasma, Mailis Tõnisson, Triin Võrno, Cathrine Lund, Knut Erik Hovda

67. Fatal iron poisoning in an adult
Jonas Höjer, Paula Hernandez

68. Toxic deaths: Data from the Poison Control Centre of Morocco (CAPM)
Naïma Rhalem, Hanane Chaoui, Lahcen Ouammi, Abdelmajid Soulaymani, Rachida Soulaymani-Bencheikh

69. Fatal intoxication with pharmaceutical agents: A 5-year epidemiological study
Julia V Radenkova-Saeva, Ralitza B Atanasova

70. A fatal case of consumption of beta-methylphenylamine, caffeine and dexamphetamine
Kai Knudsen

71. Characteristics of deaths with detection of opioids in the body: Preliminary results
Sophie Garapon, Nathalie Grosleron-Gros, Véronique Dumestre, Régis Bédry, Jean Hiquet, Emilie Christin, Sophie Gromb-Monnoyeur

Forensic toxicology

72. Drug-facilitated sexual assaults in Italy: Final data of the VARD (Violence And date Rape Drugs) project
Sarah Vecchio, Emanuela Cortini, Francesca Chiara, Eleonora Buscaglia, Sabina Strano Rossi, Giovanni Serpelloni, Carlo A Locatelli

73. Use of incapacitating substances to commit robberies: The Italian experience
Sarah Vecchio, Emanuela Cortini, Monia Aloise, Eleonora Buscaglia, Sabina Strano Rossi, Giovanni Serpelloni, Carlo A Locatelli

74. The prevalence of marijuana in fatalities involving operators of motor vehicles in Denver County, Colorado, USA
Christopher O Hoyte, James Caruso
75. Characteristics of telephoned poisons information enquiries arising from British prisons: A report from the UK National Poisons Information Service (NPIS)
   Patricia Gilmore, Peter Holmes, Leonard C Hawkins, Michael Eddleston, John P Thompson, J Allister Vale, Simon HL Thomas

76. Poison center utilization by law enforcement personnel
   J Priyanka Vakkalanka, Anjali Kapil, Joshua D King, Christopher P Holstege

77. Utilization of uniform crime reports and poison center data to identify patterns in substance abuse
   J Priyanka Vakkalanka, Emma Kingsbury, Joshua D King, Christopher P Holstege

78. Penetrating trauma and overdose: An uncommon combination in complex suicide attempts
   Matthew K Griswold, Katherine L Boyle, Kavita M Babu, Jon D Dorfman

**Veterinary toxicology**

79. Severity of cholinergic side-effects after therapeutic use of the organophosphate diazinon (dimpylate) to combat flea infestations in cats and dogs
   Anne A Kan, Marieke A Dijkman, Jan Meulenbelt, Irma de Vries

80. Be aware of renal toxicity in dogs following a small ibuprofen overdose
   Marieke A Dijkman, Anne Kan, Jan Meulenbelt, Irma De Vries

81. Common toxic exposures of animals in the Netherlands: A report from the Dutch National Poisons Information Center
   Anne A Kan, Henneke N Mulder-Spijkerboer, Marieke A Dijkman, Irma de Vries, Jan Meulenbelt

82. Is Vipera berus antivenom needed for pet treatment?
   Marieke A Dijkman, Anne A Kan, Gerard Willemse, Jan Meulenbelt, Irma De Vries

83. Toxic effects due to ingestion of Tradescantia spathacea (Sw.) leaves by an adult dog
   Eduardo M De Capitani, Jessica S Cunha, Silvia RC Gattai, Carla F Borrasca-Fernandes, Julie HA Dutilh

84. Ingestion of Amanita pantherina in a dog
   Kristin O Seljetun, Jartrud W Skjerdal, Astrid Mordt

85. Lethal mushroom poisoning in a dog
   Kristin O Seljetun, Helga R Lorentzen, Frederik L Dolva

86. Toxic deaths in cats and dogs reported to the Veterinary Poisons Information Service
   Nicola Bates, Nick Edwards
87. Liquid detergent capsule exposure in cats and dogs
   Andreia A De Sousa, Stella Matumo, Nick Edwards.

88. Lipid infusion: An analysis of cases reported to the Veterinary Poisons Information Service (VPIS)
   Philip Rawson-Harris, Nicola Bates, Nick Edwards

89. Palm oil ingestion in dogs
   Nicola Bates, Jane Ellison, Nick Edwards

90. Canine exposure to jellyfish
   Nicola Bates, Philip Rawson-Harris, Nick Edwards

91. Diclofenac ingestion in dogs: What are the risk factors associated with clinical signs?
   Philip Rawson-Harris, Nicola Bates

92. Electronic cigarette ingestion in dogs
   Nicola Bates, Joanna Crouchley, Nick Edwards

93. Nitroxynil causes severe hyperthermia in dogs
   Nicola Bates, Nick Edwards

94. Adder antivenom: The experience and opinions of veterinary professionals in the United Kingdom
   Nicola Bates, Nick Edwards

Animal poisoning

95. A multicentre cohort study of snake envenoming defines clinical syndromes and influences clinical practice
   Geoffrey K Isbister, Nicholas A Buckley, Colin B Page, Simon GA Brown

96. Novel ciguatera shellfish poisoning (CSP) cluster after consumption of Tectus niloticus, a gastropod, in Nuku-Hiva, French Polynesia
   Davide Lonati, Clémence M Gatti, Arturo Zancan, H Taiana Darius, Myriam Fleure, Mireille Chinain, Michelangelo Buonocore, Carlo Alessandro Locatelli

97. Viper envenomation in Italy: Clinical course, laboratory investigations and antivenom treatment in a case series (2002-2012) from Pavia Poison Centre
   Andrea Giampreti, Gianluca Melatini, Davide Lonati, Sarah Vecchio, Valeria M Petrolini, Francesca Chiara, Monia Aloise, Marta Crevani, Carlo A Locatelli

98. A novel strategy for identifying Naja atra species-specific venom antigen C3 for developing cobra snakebite confirmation test in Taiwan
   Chih-Chaun Lin, Chien-Chun Liu, Jau-Song Yu
99. Incidence and clinical characteristics of lionfish poisoning in Martinique
   
   Dabor Resiere, Laura Cerland, Ruddy Valentino, Cyrille Chabartier, Stephane Kaidomar, Luc De Haro, Bruno Megarbane, Hossein Mehdaoui

100. Severe envenomation by Bothrops venezuelensis
   
   Katrin Faber, Daniel Tuchscherer, Maria Martinez, Joan Fuchs, Dimitios A Tsakiris, Katharina E Hofer

101. Treatment of black widow spider (Latrodectus mactans) envenomation: A review of 53 cases
   
   Eleni Basanou, Angeliki Kalostou, Vassiliki Sofidiotou, Kostas Fountas, Diomedes Kalantzopoulos, Vassiliki Papanathanassiou, Polyxeni Neou

102. Coral snake bites in Brazil: A review
   
   Fabio Bucaretchi, Eduardo M De Capitani, Stephen Hyslop, Cinthia K Rodrigues, Marlene Zannin, Nelson J Da Silva, Jose Yamin Risk, Luciana L Casais E Silva

103. Multidisciplinary proposal of loxoscelism management: A clinical case
   
   Giscardo F Panzavolta, Andrea Stella, Maria Laura Zuccoli, Ilaria Rebotti, Fabrizio Sesana, Fabio S Garuti, Roberto Funagalli, Franca Davanzo

104. A snake bite by Dinniki´s Viper
   
   Verena Schrettl, Norbert Felgenhauer, Florian Eyer

105. Viper bites on the left and right hand side of the River Rhine: Comparison of experiences in the poisons centres in Freiburg and Strasbourg
   
   Uwe Stedtler, Christine Tournoud, Francoise Flesch, Maren Hermanns-Clausen

**Poisoning in specific populations**

106. Specific issues of the clinical picture and evolution in acute toxic methemoglobinemia in children
   
   Viorela Nitescu, Dora Boghitoiu, Iuliana Gherlan, Catalin Stemate, Doina Coman, Alexandru Ulmeanu, Coriolan Ulmeanu

107. Unintentional medication errors in children under the age of 1-year reported to the National Poisons Information Centre of Ireland
   
   Nicola Cassidy, John X Herbert, Patricia B Casey, Edel Duggan

108. Self-poisoning in the elderly: A 10-year observational study
   
   Emma E Morrison, James W Dear, Euan A Sandilands

109. Analysis of enquiries about antiretroviral therapy (ART) involving neonates, as reported to the UK National Poisons Information Service (NPIS)
   
   Rebecca ML Waugh, Muhammad EMO Elamin, Lucy C Peart, J Allister Vale, John P Thompson, Michael Eddleston, Simon HL Thomas
110. Paracetamol toxicity in an extremely preterm neonate after an inadvertent intravenous overdose: A case report
   
   
   Pirjo I Tynjälä, Janne T Backman, Maria Karjalainen, Kalle Hoppu

111. Child poisonings with methadone in France: A 6-year prospective national survey since the availability of capsules in 2008
   
   Luc de Haro, Cyndie Picot, Mathieu Glaizal, Romain Torrents, Florence Cardona

112. Cluster of naphazoline and phenylephrine intoxications in children due to a compounding pharmacy error
   
   Yves Haerden, Elisabeth Goossens, Martine Mostin

113. Long-term effects of vitamin D poisoning in children
   
   Evgeny A Luzhnikov, Galina N Sukhodolova, Yury N Ostapenko, Liliya A Kovalenko, Alexander S Kovalchuk

114. Methemoglobinemia due to dapsone in a child: Follow up after therapeutic intervention using non-invasive pulse co-oximeter
   
   Eduardo M De Capitani, Carla F Borrasca-Fernandes, Fábio Bucarectchi

115. Chronic ayurvedic medicine use in pregnancy associated with fetal abnormalities
   
   Anselm Wong, Paul I Dargan, Zeff Koutsogiannis, Shaun L Greene

116. Poisoning exposures in infants: Data from the Tygerberg Poison Information Centre, Cape Town, South Africa
   
   Carine J Marks, Daniel J Van Hoving, Cherylynn A Wium, Catherina E Du Plessis

117. Cardiac ischemia and rhabdomyolysis associated with 2,4-dinitrophenol misuse for weight loss and body building in a pediatric patient
   
   Philip Craven, Casey Turner, Brian Galovic, E Martin Caravati

118. Levetiracetam intoxication in a preterm infant due to a medication error
   
   Emma Talikka, Kalle Hoppu, Pirjo Tynjälä, Liisa Rovamo

119. Effects on the neonate of maternal abuse of drugs during pregnancy
   
   Purificación Ventura Facíl, Pilar Samper Villagrasa1, Sebastian Menao Guillen2, Clara Serrano Ferrer2, Ana Ferrer Dufo12.

120. Head injury or intoxication? Unidentified eye drop ingestion resulting in naphazoline toxicity in a toddler
   
   Hwee Min Lee, Andis Graudins

121. Acute poisoning in patients with mental disorders
   
   Julia V Radenkova-Saeva, Anelia M Loukova
122. Toxic coma in children and related mortality: A retrospective study of 9 years in a Pediatric Emergency Department

   *Simona Stanca, E Madalina Petran, Coriolan E Ulmeanu*

123. Accidental hashish ingestion in children: A Pavia Poison Centre case series

   *Monia Aloise, Andrea Giampretti, Sarah Vecchio, Valeria M Petrolini, Davide Lonati, Carlo A Locatelli*

124. Accidental ingestion of Portion snus may cause delayed onset of symptoms

   *Merethe M Schei, Liv IF Beck, G Vibeke Bakken*

125. Poisoning by substances of abuse among children: Data from the Moroccan Poison Control Center, 2008-2012

   *Hanane Chaoui, Naima Rhalem, Mohamed Badri, Lahcen Ouammi, Abdelmajid Soulaymani, Rachida Soualymani Bencheikh*

126. Severe acute poisoning in children: A 5-year retrospective study

   *E Madalina Petran, Simona Stanca, Coriolan E Ulmeanu.*

127. Pharmacovigilance in pediatrics: Medication errors reported to National Milan Poison Control Center

   *Maria L Zuccoli, F Giscardo Panzavolta, Laura Settimi, F Andrea Stella, M Adriana Tomoiaga, Leonardo Molino, Marcello Ferruzzi, Fabrizio Sesana, Franca Davanzo*

128. Suicidal adolescents: Examining self-poisonings within the pediatric population

   *Lynn A Farrugia, Katherine L Boyle, Jennifer L Carey, on behalf of the Toxicology Investigators Consortium*
**Critical care**

137. Rapid cooling via ice water submersion for severe drug-induced hyperthermia  
   *Larissa K Laskowski, Adaira Landry, Susi U Vassallo, Robert S Hoffman*

138. Toxic exposures in young children resulting in tracheal intubation  
   *Benjamin W Hatten, Gillian A*

139. Too bad to be true? Osmol gap >300 mOsm/L  
   *Vincent Nguyen, Scott N Lucyk, Mary Ann Howland, Mark K Su, Lewis S Nelson*

140. Severe hypertensive crisis and takotsubo cardiomyopathy after intrathecal clonidine pump failure  
   *Varuna Ruggoo, Hwee Min Lee, Andis Graudins*

141. Special populations: Pediatric propofol infusion syndrome treated with extracorporeal membrane oxygenation, hemodialysis and carnitine  
   *Rebecca E Bruccoleri, Diana J Felton, Michele M Burns*

142. Air transport of a severe salicylate intoxicated patient: Unforeseen risks  
   *Rita G McKeever, Gregory S LaSala, David Vearrier, Michael I Greenberg*

143. Intoxicated ICU patients: Not only high long-term mortality but also high risk for a low quality of life  
   *Raya Brandenburg, Ivo W Soliman, Jan Meulenbelt, Dylan W de Lange*

144. Critical limb ischemia after intra-arterial injection of dissolved clorazepate dipotassium tablets  
   *Jochen Stenzel, Ursula Tanase, Gabriele Dostal, Norbert Felgenhauer, Florian Eyer*

145. Pentobarbital coma with loss of pupillary light reflex  
   *Gregory S LaSala, Kara J Sexton, Jolene Okaneku, Casey Hand, David Vearrier, Michael I Greenberg*

146. Compartment syndrome secondary to neuroleptic malignant syndrome  
   *Gregory S LaSala, David Vearrier, Michael I Greenberg*

147. Acute fulminant fat embolism syndrome following high-volume intramuscular and accidental intravascular injection of paraffin/oil - based steroid solution  
   *Mathias Hjort, Lotte CG Hoegberg, Merete Almind, Tejs Jansen*

148. Multiple intensive care admissions associated with analytically confirmed recreational use of phenibut ([β]-phenyl-[γ]-aminobutyric acid) purchased over the Internet  
   *Anselm Wong, Mark Little, David Caldicott, Chris Easton, Daniel Andres, Shaun L Greene*

149. How to evaluate the severity of lithium-poisoned patients admitted to the intensive care unit?  
   *Dominique Vodovar, Emmanuel Curis, Souleiman Elbalkhi, Bruno Mégarbane*
150. Admission criteria in pediatric intensive care units in acute poisoning
\textit{Coriolan Ulmeanu, Florin Rusu, Anca Slavila, Irina Davidescu, Cristian Tanase, Dan Gavrus, Valeria Vlasceanu, Iuliana Gherlan, Dora Boghitoiu, Viorela Nitescu}

151. Prolonged mixed metabolic and toxic encephalopathy in carbamazepine poisoning
\textit{Radu Macovei, Ilenuta Danescu, Genica Caragea, Mihai Ionica}

152. Acute lipoid pneumonia presenting as acute coronary syndrome in an amateur fire breather
\textit{Michael C Galante, Mark D Levine}

153. Paroxysmal atrial fibrillation after cannabis smoking
\textit{Ilenuta Danescu, Radu Macovei, Genica Caragea, Mihai Ionica}

154. Atypical neuroimaging findings in a patient presenting with overdose: A case report
\textit{Jawaid Akhtar, Emily Brant, Daniela Morato, Joseph H Yanta}

155. Clinical profile, management and outcomes of severely poisoned patients requiring critical care: Experience of a poison treatment centre in Hong Kong
\textit{Raymond SM Wong, Jones CM Chan, Suet-Li Yuen, Yuen-Sim Wong, James MH Ng, Thomas YK Chan}

\textbf{Poisoning management}

156. Analysis of clinical factors that predict diagnosis in suspected acute poisoning
\textit{Robert Camilleri}

157. Analysis of risk factors that predict severity of acute poisoning
\textit{Robert Camilleri}

158. Importance of abdomen CT scan and gastroscopic pharmacobezoar removal following massive acute drug overdose
\textit{Filippo Gori, Marco Cirronis, Alessandra Ieri, Valentina Galli, Francesco Gambassi, Manuela Bonizzoli, Laura Tadini Boninsegni, Guido Mannaioni}

159. Endoscopic retrieval of enteric-coated aspirin tablets in massive overdose
\textit{Ann M Arens, Hallam M Gugelmann, Salman A Rhaman, Craig Smollin}

160. Acute poisonings and rhabdomyolysis: A 10-year retrospective study in a medical university clinic
\textit{Marie Vangstad, Mari A Bjornaas, Dag Jacobsen}

161. Modern intermittent haemodialysis (IHD) is an effective method of removing salicylate in chronic topical salicylate toxicity
\textit{Anselm Wong, Kathy Mac, Anders Aneman, Jeffrey Wong, Betty S Chan}

162. Massive carbamazepine overdose treated with continuous veno-venous hemodialysis
\textit{Craig Smollin, Annie Arens, Mathew S Petrie, Thomas Kearney}
163. Accidental intrathecal administration of bleomycin: Favourable outcome after cerebrospinal fluid exchange
   Judith Cottin, Elodie Jean-Bart, Jean M Sapori, Alexandre Pirollet, Marie C Perrin, Thierry Vial

164. Complete spinal paralysis following a brachial plexus block treated with lipid infusion
   Richard D Shih, Diane Calello

165. Hemodialysis in glycine toxicity
   Christopher Styles, Richard D Shih, Diane Calello

166. Safety and efficacy of phenobarbital for benzodiazepine detoxification
   Maria Sili, Francesco Gambassi, Carlo Smorlesi, Brunella Occupati, Guido Mannaiioni

167. Treatment of hospitalized acute poisonings in Estonia (EstTox 2009)
   Raido Paasma, Triin Vörno, Cathrine Lund, Knut Erik Hovda

168. Ventricular tachycardia in mixed drug overdose treated successfully with lidocaine and magnesium sulfate
   Ching-Hsing Lee, Chun-Kuei Chen, Meng-Huan Wu

169. Isoniazid poisoning: Pharmacokinetics and effect of dialysis after massive ingestion
   Kirsty Skinner, Ana Saiao, Ahmed Mustafa, Jessica Soderstrom, Gregory Medley, Michael S Roberts, Geoffrey K Isbister

170. Intravenous lipid emulsion for treatment of local anesthetic systemic toxicity
   Andrea Stella, F Giscardo Panzavolta, Fabrizio Sesana, Maria L Zuccoli, Valeria Dimasi, Marcello Ferruzzi, Paolo Severgnini, Franca Davanzo

Chemical poisoning

171. Acute renal failure and neurological damage after topical application of brake fluid containing diethylene glycol
   Sarah Vecchio, Valeria M Petrolini, Davide Lonati, Andrea Giampreti, Laura Zaratin, Rita Bertuetti, Carlo A Locatelli

172. How common are exposures to soluble film automatic dishwashing products in the UK? A retrospective UK National Poisons Information Service (NPIS) study conducted from January 2008 to October 2014
   Rachael C Day, Michael Eddleston, Simon HL Thomas, John P Thompson, J Allister Vale

173. Has the International Association for Soaps, Detergents and Maintenance Products (AISE) product stewardship programme had an impact on the number of liquid laundry detergent capsule exposures reported to the UK National Poisons Information Service (NPIS)?
   Rachael C Day, Michael Eddleston, Simon HL Thomas, John P Thompson, J Allister Vale
174. Incidence of carbon monoxide intoxication in Belgium
   Marijke Fortuin, Bernadette Tissot, Martine Mostin

175. Acute pulmonary injuries from chlorine-based swimming pool disinfectants in northern Germany
   Martin Ebbecke, Rafael Wagner, Herbert Desel, Andreas Schaper

176. MAGAM II: Prospective observational multicentre poisons centre study on eye exposures caused by cleaning products
   Maren Hermanns-Clausen, Herbert Desel, Elke Färber, Carola Seidel, Angelika Holzer, Florian Eyer, Antje Engel, Dagmar Prasa, Erol Tutdibi, Andreas Stürer

177. Trends in cyanide exposures reported to the UK National Poisons Information Service (NPIS) from 2008 to 2012
   Nicola Wheatley, Gillian A Cooper, John P Thompson, J Allister Vale, Michael Eddleston, Simon HL Thomas, James M Coulson

178. Epidemiology and clinical characteristics of hydrofluoric acid (HF) exposures: 6-years’ experience of the Pavia Poison Control Centre
   Davide Lonati, Sarah Vecchio, Andrea Giampreti, Valeria M Petrolini, Marta Crevani, Carlo A Locatelli

179. A rare complication of ethyl acetate poisoning
   Chun Kuei Chen

180. Caustic exposures reported to the Belgian Poison Centre
   Geert Verstegen, Martine Mostin

181. Serious magic-nano-like lung oedemas caused by a liquid stain protection product: Using two new tests as a combined screening tool for aerosol products
   Axel Hahn, Monika Fischer, Dorothee Walter, Clemens Dasenbrock, Wolfgang Koch, Kathrin Begemann, Matthias Greiner

182. Delayed life-threatening airway edema after caustic ingestion in a child
   Daniel J Sessions, Vikhyat S Bebarta, Joseph K Maddry

183. Kettle descalers: A brewing issue
   Gloria Alldridge, Stephen Jones, J Allister Vale, Michael Eddleston, Simon HL Thomas, John P Thompson

184. Update: Cases of aerotoxic syndrome reported to BfR
   Nina Glaser, Kathrin Begemann, Esther Feistkorn, Axel Hahn

185. Drinking strep test reagents: A case of nitrite poisoning
   Vivian M Dalaker, Odd Martin Vallersnes, Linn E Fosshaug, Kirsti S Andersson, Knut Erik Hovda
186. Carbon monoxide poisoning: Comparison between French and German monitoring systems
   Christine Tournoud, Uwe Stedtler, Laurent Berthelon, Maren Hermanns-Clausen, Ingrid Blanc,
   Françoise Flesch

187. Liquid laundry pods on either side of the Rhine
   Christine Tournoud, Uwe Stedtler, Maren Hermanns-Clausen, Ingrid Blanc, Laurent Berthelon,
   Françoise Flesch

188. Current status of carbon monoxide poisoning in Belgium
   Marijke Fortuin, Martine Mostin

189. Pediatric exposures to laundry detergent capsules
   Anna Celentano, Fabrizio Sesana, Laura Settini, Giordano Felice, Leonardo Molino, Beatrice
   Giliotti, Ilaria Rebutti, Valeria Dimasi, Franca Davanzo

190. Inquiries to the New Zealand Poisons Centre concerning exposures to aerosol oven cleaners
   Richard W Mason, Robin J Slaughter

191. The European Chemical Emergency Network (ECHEMNET): An EU-level network of experts to
     respond to cross-border chemical incidents
   Charlotte V Hague, Rob Orford, Herbert Desel, Andreas Schaper, Lisbeth Hall, Sally Hoffer, Ann
   Goransson Nyberg, Per Leffler, Elisabeth Wigenstam, Agneta Plamboeck, Jiri Trnka, Maria del
   Carmen García Cazalilla, Jesus Ocaña García-Donas, Jose Javier García del Aguilá, Raquel Duarte-
   Davidson

192. Reports on cases of poisoning from eye exposure, in particular, detergents and cleaning agents
   Kathrin Begemann, Nina Glaser, Matthias Greiner

193. Spurious serum chloride measurement in severe metabolic disturbance associated with 2-
     butoxyethanol ingestion
   Michael A Downes, Ingrid L Berling, Tim H Stanley, Geoffrey K Isbister

194. Retrospective analysis of oral exposure to vinegar essence in Austria, 2002-2013
   Tara Arif, Kinga Bartekca-Mino, Helmut Schiel, Angelika Holzer, Dieter Genser

195. Fear of secondary exposure of healthcare personnel can lead to disproportionate measures
   Ronald de Groot, Antoinette JHP van Riel, Gerard A van Zoelen, Marianne EC Leenders, Irma de
   Vries, Jan Meulenbelt

196. Dichloroethane as a cause of Parkinsonism: A case report
   Jonas Surkus, Kristina Lauckaite, Danguole Surkiene, Ruta Leksiene, Marius Perminas

197. Ethylene glycol poisonings associated with acute kidney injury in the Slovak Republic
   Silvia Plackova, Blanka Caganova, Petra Faltanova, Tomas Liptak, Olga Otrubova, Jaroslav
   Kresanek
198. Complicated diagnosis of ethylene glycol poisoning: A case report
   Ruta Leksiene, Laima Peleckaite, Inga Skarupskiene, Asta Stankaviene, Jonas Surkus, Vytautas Kuzmiskis, Inga Arune Bumblyte, Edita Ziginskiene

199. Dishwasher tablets: Corrosive or irritant following accidental exposure?
   Feargal O’ Connor, Patricia B Casey, Edel Duggan

200. Extensive rhabdomyolysis enhanced acute renal failure in a severe delayed ethylene glycol poisoning
   Ilenuta Danescu, Radu Macovei, Genica Caragea, Mihai Ionica

201. Hydrogen sulfide poisonings in Denmark 2004-2014
   Julie Volk, Niels E Ebbehøj

202. The dangers of chlorinated pools: A case of severe keratitis and episcleritis
   Mara Pisani, Davide Lonati, Giorgia Bottaro, Annamaria C Musolino, Umberto Raucci, Massimo Crisogiani, Marco Marano

203. Use of a polyamphoteric solution in the event of ocular and cutaneous chemical accidents: 12 cases
   Jean-Luc Fortin, Philippe Paulin, Marie-Pierre Bitar, Jacqueline Payre, François Ravat, Lucien Bodson, Jean-Michel Macher

204. The effectiveness of patient-tailored treatment for acute organophosphate poisoning
   Chih-Chuan Lin, Dong-Zong Hung, Hsien-Yi Chen, Kuang-Hung Hsu

Pesticide poisoning

205. Acute human toxicity of emamectin
   Wang TeHao, Wu Ming-Ling, Ger Jin, Tsai Wei-Jen, Deng Jou-Fang, Yang Chen-Chang

206. PiCCO interpretation for acute glyphosate intoxication with shock: favor cardiogenic shock
   Cho Ju Wu, Chih Chuan Lin

207. Glyphosate intoxication resulting in ventricular dysrhythmias and cardiogenic shock
   I-Lin Wu, Chih-Chuan Lin

208. Acute poisoning with the neonicotinoid insecticide imidacloprid misdiagnosed as organophosphate intoxication
   Shih-Hao Wu, Chun-Kuei Chen, Chih-Chuan Lin

209. Successful treatment with hemodialysis for acute renal failure after glyphosate poisoning: A case report
   Meng-Huan Wu, Ching-Hsing Lee
210. Chlorfenapyr Intoxication: A fatal case with acute pancreatitis
   Hung-Sheng Huang, Chih-Chuan Lin

211. Cardiovascular findings in a prospective case series of fatal diazinon poisoning in children
   C Iolanda Vivisenco, Coriolan E Ulmeanu

212. Acute pancreatitis in carbofuran poisoning: A case report
   Ilenuta Danescu, Radu Macovei, Genica Caragea, Mihai Ionica

213. A dangerous sip: Acute copper nitrate accidental poisoning in a child
   Andrea Giampreti, Monia Aloise, Valeria M Petrolini, Anna Ronchi, Carlo A Locatelli

214. Sodium monofluoroacetate-induced coma reversed by acetamide administration
   Jones CM Chan, James MH Ng, Raymond SM Wong, Thomas YK Chan, Mo-Lung Chen, Judy SY Lam

215. Epidemiology of acute pesticide poisoning in Greece: A 2-year analysis
   Chrysanthi Kafkala, Angeliki Kalostou, Eleni Basanou, Kostas Fountas, Vassiliki Sofidiotou, Spyridoula Zoniou, Polyxeni Neou

216. Severe amitraz poisoning in a teenager
   E Madalina Petran, Simona Stanca, Coriolan E Ulmeanu

217. Severe but reversible toxicity with aldicarb ingestion
   Adam Michael, Ahmed Mustafa, Gregory Medley, Jeffrey Grice, Michael S Roberts, Geoffrey K Isbister

218. Two cases of severe methomyl pesticide intoxication
   Byung Hak So, Kyungman Cha

Metal poisoning

219. Massive parenteral manganese overdose: Minimal role for hemodialysis
   Elizabeth Q Hines, Irfana Soomro, Mary Ann Howland, Robert S Hoffman, Silas W Smith

220. Pregnancy outcome after metal-on-metal hip arthroplasty: A case report
   Chiara Pracucci, Isabella Orsini, Maria Cristina Aprea, Brunella Occupati, Guido Mannaioni, Carlo Smorlesi, Francesco Gambassi, Alessandra Pistelli

221. BfR case series of elevated metal levels caused by metal-on-metal implants
   Axel Hahn, Kathrin Begemann, Esther Feistkorn, Matthias Greiner

222. Evaluation of human cases with elemental and inorganic mercury exposure compared to German human biomonitoring (HBM) values
   Axel Hahn, Maren Prochnow, Kathrin Begemann, Esther Feistkorn
223. Assassination with arsenic: A special case  
   Marianne EC Leenders, Ronald De Groot, Irma De Vries, Jan Meulenbelt

224. Risk of lead poisoning in patients with retained lead fragments in the body  
   Claire Masson-Samoïault, Régis Bédry, Estelle Sudre, Pierre Brun, Nahid Nadjimi-Sarram, Sophie Gromb-Monnoyeur

225. Cobalt cardiotoxicity in a patient with bilateral metal-on-metal (MoM) arthroplasty  
   Christine Payen, Corine Pulce, Jean-Marc Sapori, Thierry Vial

**Food poisoning**

226. Clinical management of foodborne botulism poisoning in emergency setting: An Italian case series  
   Davide Lonati, Luigi Flore, Sarah Vecchio, Andrea Giampreti, Valeria M Petrolini, Fabrizio Anniballi, Dario De Medici, Carlo A Locatelli

227. Botulism caused by vacuum packed whitefish (Corregonus lavaretus)  
   Mark Personne, Ann-Sofi Skagius

228. Dangerous palytoxin exposure after boiling coral  
   Emanuela Cortini, Davide Lonati, Valeria M Petrolini, Andrea Giampreti, Aurelia Tubaro, Carlo A Locatelli

229. LSD poisoning after ingestion of contaminated beef in a family of four  
   Alfred Aleguas, Julia M Pearson, Tamas R Peredy

230. Deadly threat in the preserving jar  
   Helmut Hentschel, Dagmar Prasa, Germaine Frimlova, Simone Just, Gisela Liebetrau, Bettina Plenert, Anne Stuerzebecher, Michael Deters

**Mushroom poisoning**

231. Accidental Panaeolus foenisecii exposures: No clinically relevant effects in children  
   Katharina M Schenk-Jaeger, Bettina Plenert, Dagmar Eckart, Bettina Haberl, Gabriele Schulze, Janine Borchert-Avalone, Uwe Stedtler, Rudolf Pfab

232. Lights and shadows of urinary amanitin concentration in clinical practice  
   Giuseppe Musella, Francesca Assisi, Franca Davanzo, Selene Gaviraghi, Adriano Masarin, Paolo Severgnini, Paola Angela Moro, Fabrizio Sesana
233. Mushrooms poisoning in Italy: A 2-year case series (2012-2013) from the Pavia National Poison Centre

Sarah Vecchio, Andrea Giampreti, Valeria M Petrolini, Davide Lonati, Francesca Chiara, Marta Crevani, Teresa Coccini, Carlo A Locatelli

234. Mushroom poisoning: A proposed new clinical classification

Julian White, Scott Weinstein, Luc De Haro, Regis Bedry, Andreas Schaper, Barry Rumack, Thomas Zilker

235. How can we reduce the number of mushroom poisonings among immigrants and tourists?

Eva K Olsson, Ulla Westberg

236. A rare case of acute renal failure related to Amanita proxima ingestion

Andrea Mancini, Pernina Angelini, Francesca Assisi, Michele Bozzi, Cristoforo Cuzola, Vincenzo Giancaspro, Elvira Laraia, Maria Teresa Nisi, Stefano Balestreri, Anna R Proscia, Giuseppe Tarantino, Ottavio Vitale, Francesco Petrarulo, Franca Davanzo

237. From delightful mushroom to poisoning: A Danish mushroom syndromes survey

Line Lydeking, Christian HR Hansen, Niels E Ebbehoej, Lotte CG Hoegberg

238. Evaluation of mushroom-related inquiries to the National Poisons Information Centre, Norway in 2013-2014

Kristin O Seljetun, Marte Espeland

239. Pediatric mushrooms poisoning: A fairy tale to warn children and adults

Fabrizio Sesana, Francesca Assisi, Rossana Borghini, Anna Celentano, Marcello Ferruzzi, Leonardo Molino, Franca Davanzo

240. Mushroom poisoning: A descriptive study of 19 cases

Ona Escoda, Santiago Nogué, Jordi To-Figuera, Gregori Casals

Plant poisoning

241. Intensive support therapy and mortality in Colchicum autumnale poisoning

Miran Brvar

242. Poisoning with Cicuta virosa in Sweden

Sonny Larsson, Ulla Westberg, Javid Hussain, Ulf Göransson

243. Nerium oleander ingestions are relatively benign

Edward P Krenzelok

244. Attempted suicide by ingestion of ricin soup

Agnes G van Velzen, Iris C van Sommeren-de Potter, Meyno O den Dulk, Antoinette JHP van Riel, Jan Meulenbelt, Irma de Vries
245. Poisoning due to Wisteria seed ingestion: The Pavia Poison Centre case series
   Marta Crevani, Valeria M Petrolini, Davide Lonati, Andrea Giampreti, Monia Aloise, Giulia Scaravaggi, Carlo A Locatelli

246. Culinary mistakes involving daffodils: Do you know your onions?
   Sian CD Harbon, Gillian A Cooper, J Allister Vale, Michael Eddleston, Simon HL Thomas, John P Thompson

247. Three 'toxic' plants
   Alison M Good, Caroline McGrory, Simon HL Thomas, John P Thompson, J Allister Vale, Michael Eddleston

248. Withdrawn

249. Acute liver injury after ingestion of rhubarb leaves: A case report
   Ruth Kastanje, Mare Oder, Kristiina Põld

250. Plants: Analysis of exposures reported to the National Milan Poison Control Center (2010-2013)
   Chiara Falciola, Maria Laura Zuccoli, Leonardo Molino, Beatrice Giliotti, Maria L Colombo, Fabrizio Sesana, Franca Davanzo

Experimental toxicology / Mechanisms of toxicity

251. Opioids may bind protein targets associated with the serotonin syndrome
   Keith K Burkhart, Darrell Abernethy

252. In vitro inhibition of aldehyde-dehydrogenase by mushroom extracts
   Rudolf Pfab, Katrin Romanek, Bettina Haberl, Florian Eyer

253. Retention memory defects of poisoning with a sarin analogue in rats rescued with atropine and pralidoxime are improved with naltrexone
   William J Meggs, Kori L Brewer, Tuan Tran

254. Withdrawn

255. A novel screening method to detect in vitro neurotoxicity: Effects of illicit drugs on neuronal activity
   Laura Hondebrink, Steffie W Drega, Regina GDM van Kleef, Remco HS Westerink, Jan Meulenberg

256. Mitochondrial toxicity of valproic acid and its reversion using L-carnitine: First results from an experimental model
   Agathe Potier, Lucie Chevillard, Patricia Risède, Kelly Da Silva, Philippe Manivet, Bruno Mégarbane
**Occupational and environmental poisoning**


> Jolene Okaneku, Rita McKeever, David Vearrier, Michael I Greenberg

258. Evaluation of clinical effects after high pressure injection injuries of the hand using 20 years’ experience of Pavia Poison Centre: A toxicological and surgical emergency

> Francesca Chiara, Davide Lonati, Andrea Giampreti, Valeria M Petrolini, Sarah Vecchio, Carlo A Locatelli

259. Unintentional needlestick injuries in livestock production

> D Michael G Beasley, Lucy M Shieffelbien, Wayne A Temple

260. Tympanic membrane perforation and cranial nerve VII and VIII injury due to a hot metal injury: A case report

> Brian Cone, Jawaid Akhtar, Nathan Menke, Emily Brant
Classic and new drugs of abuse

270. Acute neuro-respiratory toxicity of 3,4-methylenedioxypyrovalerone: An experimental study in the rat
   Nadia Benturquia, Lucie Chevillard, Cyril Masniere, Nihad Hamadco, Olivier Roussel, Patricia Risède, Jacques Callebert, Paul Dargan, Bruno Mégarbane

271. Do users of novel psychoactive substances take what they think they take? An overview of drug product contents analysed within the Swedish STRIDA project
   Matilda Bäckberg, Erik Lindeman, Olof Beck, Karl-Henrik Jönsson, Anders Helander

272. Increased use of new psychoactive substances (NPS) in the Netherlands
   Johanna J Nugteren-van Lonkhuyzen, Laura Hondebrink, Daan van der Gouwe, Tibor M Brunt

273. Nopaine No Gain: A case of recreational ethylphenidate toxicity
   George P Bailey, James H Ho, Simon Hudson, John RH Archer, Paul I Dargan, David M Wood

274. Acute autonomic and psychotropic effects of LSD in healthy subjects in a placebo-controlled study
   Yasmin Schmid, Patrick C Dolder, Matthias E Liechti

275. MDPV in Sweden: Checked-in, never left. Differences in market cycles of Novel Psychoactive Substances
   María Enghag, Karin Feychtting, Erik Lindeman

276. Acute intoxications by synthetic cannabinoids in the emergency system: An Italian cases series
   Carlo A Locatelli, Sarah Vecchio, Andrea Giampreti, Eleonora Buscaglia, Azzurra Schicchi, Pierangela Grignani, Giovanni Serpelloni

277. Bad trip due to 25I-NBOMe: A case report from the EU Project SPICE II Plus
   Maren Hermanns-Clausen, Verena Angerer, Josephine Kithinji, Christina Grumann, Volker Auwärter

278. Emergency department admissions due to disulfiram-ethanol interaction
   Kristof Segher, Walter Buylaert, Peter De Paepe

279. Withdrawn

280. Laboratory confirmation of recreational drugs in Oslo, Norway
   Per Sverre Persett, Odd Martin Vallersnes, Elisabeth L Øiestad, Ritva Karinen, Stig Tore Bogstrand, Fridtjof Heyerdahl, Knut Erik Hovda
281. Acute poisoning by DOC (2,5-dimethoxy-4-chloroamphetamine): Report of 6 cases presenting together at the Emergency Department

Jorge Navarro Calzada, Roman Royo Hernandez, Sergio Duerto Cebollada, Emilia Civeira Murillo, Sebastian Menao Guillen, Ana Ferrer Dufol

282. Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland

Evangelia Liakoni, Patrick C Dolder, Katharina Rentsch, Matthias E Liechti


Dieter Müller, Hartmud Neurath, Simone Just, Gesine Liebetrau, Herbert Desel

284. Diffuse alveolar hemorrhage following synthetic cannabinoid abuse

Danielle K Matilsky, Kevin Davey, Allegra Long, David Terca, Jason Chu

285. Psychosis associated with acute poisoning by recreational drugs and novel psychoactive substances: A European case series from the Euro-DEN project

Odd Martin Vallersnes, Alison M Dines, David M Wood, Christopher Yates, Fridtjof Heyerdahl, Knut Erik Hovda, Isabelle Giraudon, Paul I Dargan, on behalf of the Euro-DEN research group

286. When a law for terrorism risk provides help in the discovery of new psychoactive substances (NPS)

Francis Grossenbacher, Jean Marc Sapor, Catherine Feliu, Jean Michel Gaulier, Helene Marty, Carole Carolet

287. Severe poisoning after nasally administered mixture of NBOMe compounds: A case report

Alexandra Boucher, Romain Hernu, Antony Citterio-Quentin, Mustapha Moulmsa, Luc Humbert, Thierry Coulon, Thierry Vial

288. Severe agitation due to novel synthetic cannabinoid abuse treated with prehospital ketamine

Janetta L Iwanicki, Whitney J Barrett, Dazhe J Cao, Jennie A Buchanan, Omeed Saghafi, Kennon J Heard, Kevin E McVaney

289. Therapeutic difficulties with a symptom-triggered regimen for alcohol withdrawal syndrome

John RH Archer, David M Wood, Anna M Watson, Paul I Dargan

290. Respiratory depression and ventilatory support in synthetic cannabinoid exposures: Report from the ToxIC Registry

Diane P Calello, Richard D Shih, Alex B Troncoso, On Behalf of the ACMT Toxicology Investigators Consortium (ToxIC)

291. Spice or marijuana: What’s the difference?

Mark Su, Maria Mercurio-Zappala, Robert S Hoffman
292. Calls to the Finnish Poison Information Centre concerning drugs of abuse 2010-2013
   Mervi Saukkonen, Sanne Toivonen, Anna-Maria Termälä, Kalle Hoppu

293. Presenting symptoms in GHB poisoned patients are independent of concomitant drugs
   Mojca Skafar, Damjan Grenc, Miran Brvar

294. Stress-induced cardiomyopathy and delayed fatal dysrhythmia after huffing of 1,1-difluoroethane
   Joseph H Yanta, James R Boulden, Andrew M King, Michael G Abesamis, Nathan B Menke

295. Levamisole: A high-risk cocaine adulterant
   Santiago Nogué, Jordi To-Figuera, Gregori Casals, José-M Mascaro, José Hernández-Rodriguez, Victor Gil

296. Mixed benzodiazepine-heroine acute toxicity is associated with more severe toxicity than heroin toxicity not associated with benzodiazepine use
   Paul I Dargan, Alison M Dines, Fridtjof Heyerdahl, Christopher Yates, Isabelle Giraudon, Knut Erik Hovda, David M Wood, on behalf of the Euro-DEN Research Group

297. Perception of prescription drug safety in an online national survey in the United Kingdom
   David M Wood, Paul I Dargan, Andrea C Besharat, Erin M Martinez, Jody L Green

298. Review of the European Drug Emergencies Network (Euro-DEN) training package for non-specialist workers to assess acute recreational drug and novel psychoactive substance (NPS) toxicity in night-time economy environments
   David M Wood, Alison M Dines, Fridtjof Heyerdahl, Christopher Yates, Isabelle Giraudon, Raido Paasme, Knut Erik Hovda, Paul I Dargan, on behalf of the Euro-DEN Research Group

299. Deaths involving recreational drugs and novel psychoactive substances reported to the European Drug Emergencies Network (Euro-DEN): A review of the first 9 months
   Alison M Dines, Paul I Dargan, Knut Erik Hovda, Fridtjof Heyerdahl, Christopher Yates, Isabelle Giraudon, David M Wood, on behalf of the Euro-DEN Research Group

**Medicine abuse**

300. Oxycodone/naloxone preparations can cause acute opioid withdrawal symptoms following intravenous and oral exposure
   Anselm Wong, Dawson Macleod, Jeff Robinson, Zeff Koutsogiannis, Andis Graudins, Shaun L Greene

301. Estimating nonmedical use of prescription opioids in the United States from social media
   Michael Chary, Nick Genes, Christophe Giraud-Carrier, Carl Hanson, Lewis Nelson, Alex F Manini

302. Dextromethorphan abuse in adolescence: A rising trend
   Blanka Caganova, Silvia Plackova, Petra Faltanova
303. Emergency Department presentations following recreational use of baclofen, gabapentin and pregabalin: A Euro-DEN case series
   *Christopher Yates, Alison M Dines, David M Wood, Knut E Hovda, Fridthjof Heyerdahl, Isabelle Giraudon, Roumen Sedefov, Paul I Dargan, on behalf of the Euro-DEN research group*

304. Acute behavioural disturbance associated with phenibut purchased via an internet supplier
   *Michael A Downes, Ingrid L Berling, Geoffrey K Isbister*

305. The rise in prescription parenteral opiate abuse: Cases reported to an Australian Poisons Information Centre
   *Nicole E Wright, Rose Cairns, Jared A Brown*

306. Trends over time in population rates of intentional misuse and self-harm mentions with buprenorphine, methadone, and oxycodone as reported to poison centres in Germany, Italy and the United Kingdom
   *Becki Bucher Bartelson, Herbert Desel, Andreas Schaper, Franca Davanzo, Fabrizio Sesana, Gillian Cooper, John P Thompson, Darcey JG Johnson, Jody L Green*

307. An Internet snapshot study to investigate the cost and availability of the novel benzodiazepines diclazepam, flubromazepam and pyrazolam in the UK
   *Rachelle Abouchedid, David M Wood, John RH Archer, Paul I Dargan*

   *Narjis Badrane, Fatima Abadi, Ahlam Meftah, Hanane Chaoui, Naima Rhalem, Rachida Soulaymani Bencheikh*

309. Prescription opioids: Reported reasons for non-medical use in an online national survey in the United Kingdom
   *Paul I Dargan, Jody L Green, Erin M Martinez, Andrea C Besharat, David M Wood*

310. Pregabalin, gabapentin and baclofen: Sources of drug acquisition for non-medical use in an online national survey in the UK
   *David M Wood, Andrea C Besharat, Paul I Dargan, Erin M Martinez, Jody L Green*

311. Chronic pain and non-medical use of opioids, benzodiazepines and pregabalin in an online national survey in the United Kingdom
   *Paul I Dargan, David M Wood, Andrea C Besharat, Erin M Martinez, Jody L Green*

312. Benzodiazepines and ÏÖ DrugsÏÖ Reported reasons for non-medical use in an online national survey in the United Kingdom
   *David M Wood, Jody L Green, Andrea C Besharat, Erin M Martinez, Paul I Dargan*

313. Characterization of acute opioid overdose in the ToxIC Registry
   *Katherine L Boyle, Lynn A Farrugia, Jennifer L Carey, on behalf of the ToxIC Consortium*
Pharmaceutical poisoning

314. Cardiovascular toxicity with levetiracetam overdose
   Colin B Page, Ahmed Mostafa, Ana Saitao, Greg Medley, Jeffrey Grice, Michael Roberts, Geoffrey Isbister

315. Methotrexate exposures reported to the Poisons Information Centre Erfurt, Germany
   Anne Stuerzebecher, Germaine Frimlova, Michael Deters, Helmut Hentschel

316. Unusual management of an inadvertent overdosage of vinorelbine in a child: A case report
   Maria L Zuccoli, F. Giscardo Panzavolta, F Andrea Stella, M Adriana Tomoiaga, Leonardo Molino, Marina Caligara, Carmelita D’Ippolito, Fabrizio Sesana, Francesca Assisi, Franca Davanzo

317. Massive paracetamol overdose
   Angela L Chiew, Geoffrey K Isbister, Nicholas A Buckley

318. Tramadol overdose is associated with an increased risk of seizure but not serotonin toxicity
   Nicole Ryan, Geoffrey K Isbister

319. Levodropropizine overdose: A multicenter analysis of poison center data
   Elke Färber, Sonja Gros, Elja Heistermann, Uwe Stedtler, Gabriele Dostal, Sabine Stoletzki, Dieter Genser, Dagmar Prasa

320. Accidental intravenous administration of haloperidol decanoate
   Valeria M Petrolini, Eleonora Buscaglia, Giulia Scaravaggi, Antonella Valli, Laura Rolandi, Carlo A Locatelli

321. New oral anticoagulants (NOACs): An increasing problem for poison centres?
   Ingo Sagoschen, Oliver Sauer, Andreas Stürer

322. A decade of Australian methotrexate dosing errors: What more can be done?
   Jared A Brown, Rose Cairns

323. High-visibility warning labels on paracetamol containing products do not prevent supratherapeutic ingestion
   Joe-Anthony Rotella, Anselm Wong, Jocelyn Howell, Amy Robotham, Shaun L Greene

324. Acute toxicity profile of tolperisone in overdose: A consecutive case series

325. Sleeping Beauty: Prolonged sedation following an alprazolam and fluconazole overdose
   Angela L Chiew, Kate Sellors, Betty Chan

326. Lack of serious cardiotoxicity in patients with desvenlafaxine overdose
   Gopi Mann, Naren Gunja
327. Patterns of toxicity of antiretroviral therapy as reported to the UK National Poisons Information Service (NPIS)
   Rebecca ML Waugh, Muhammad EMO Elamin, Lucy C Peart, J Allister Vale, John P Thompson, Michael Eddleston, Simon HL Thomas

328. Overdoses of riluzole reported to the UK National Poisons Information Service
   Alison M Good, Caroline McGrory, Simon HL Thomas, John P Thompson, J Allister Vale, Michael Eddleston

329. Severe lithium poisoning: A case series from Norway
   Mari A Bjornaas, Knut E Hovda, Anne K Fagerheim, Rune T Simonsen, Dag Jacobsen

330. Two years of paracetamol misdosing: The experience of National Milan Poison Control Center
   Maria L Zuccoli, F Giscardo Panzavolta, F Andrea Stella, M Adriana Tomoiaga, Angelo Travaglia, Leonardo Molino, Fabrizio Sesana, Franca Davanzo

331. Duloxetine overdose: A case series
   Simone Just, Sonja Gros, Cornelia Reichert, Elja Heistermann, Petra Hoffmann-Wahlbeck, Uwe Stedler, Carola Seidel, Elke Färber, Sabine Stoletzki, Gabriele Dostal, Dieter Genser, Dagmar Prasa

332. Changes to prescribed psychotropics following intentional overdose
   Lynn A Farrugia, Emily Gordon, Alexandra Sanseverino, Sean H Rhyee

333. Serum warfarin concentrations and corresponding INR after intentional warfarin overdose
   Annie M Arens, Shogo J Miyagi, Timur Durrani, Howard T Horng, Craig Smollin

334. Prolonged, refractory glyburide and nateglinide toxicity in the setting of acute renal failure
   Jennifer C Cabot, James S Morrison, Alex F Manini

335. A survey of doctors' knowledge and confidence in managing paracetamol toxicity
   Wui-Ling Chan, Dong-Haur Phua

336. Acute poisoning with diuretics, antihypertensive and antiarrhythmic medicines
   Rayna D Stoyanova, Julia V Radenkova-Saeva

337. A case of severe overdose with valproic acid treated with carnitine and continuous renal replacement therapy (CRRT)
   Kai Knudsen

338. Acute liver injury after low doses of acetaminophen by intravenous route in an alcoholic patient
   Francis Grossenbacher, Catherine Feliu, Zoubir Djerada, Veronica Pinel Petit, Carole Carolet, Bruno Lafon

339. The incidence of tramadol-related seizures is affected by co-ingestants
   Brett A Roth, Mathias B Forrester, Miguel C Fernandez, Masoumeh Ghiavand
340. APAP x AT in staggered, chronic and time unknown acetaminophen overdoses
   Nicholas E Nacca, Michael Hodgman

341. 5-Oxoproline concentrations in acetaminophen overdose
   Mary S Paden, Michael Mullins, Evan Schwarz, Dennis Dietzen, Robert Nerenz, David Liss

342. Toxicity of desvenlafaxine in overdose
   Ioana A Vlad, Jason M Armstrong

Adverse drug reactions

343. Mortality predictors in lactic acidosis with confirmed serum metformin concentration
   Daniel Morell-García, Loreto Quesada Redondo, Emilia Civeira Murillo, Isabel Gomila Muñiz, Juan Robles Bautz, Andrés Carrillo López, Jordi Puiguriguér Ferrando, Ana Ferrer Dufol, Bernardino Barceló Martín

344. Lithium chronic and acute-on-chronic poisoning: A retrospective case series
   Viola Mazzucco, Lara Bertieri, Primo Botti, Francesco Gambassi, Andrea Missanelli, Emanuela Masini, Guido Mannaioni

345. A severe adverse drug reaction related to Deferasirox
   Marco Marano, Mara Pisani, Corrado Cecchetti, Bianca M Goffredo, Matteo Di Nardo, Federico Deodato, Davide Lonati, Francesca Stoppa, Alessandra Simula

346. Severe adverse drug reactions and anaesthesiologic intervention: Experience of the National Milan Poison Control Centre
   F Giscardo Panzavolta, Carlotta Boselli, Marcello Ferruzzi, Rossana Borghini, Fabrizio Sesana, Franca Davanzo

347. Rhabdomyolysis and acute renal injury associated with nutritional supplements containing stimulants to enhance body building
   William J Meggs, Kathleen K Bryant, Mohan Punja, Susan P Miller, Juan A March

348. Supratherapeutic doses of opiates for acute pain crisis in the ED are safe
   Gregory S LaSala, Jena Lee, James R Roberts

349. Post-injection delirium/sedation syndrome after olanzapine long-acting injection: Experience of the Milan Poison Center
   Giscardo F Panzavolta, Andrea F Stella, Maria L Zuccoli, Adriana M Tomoiaga, Angelo Travaglia, Fabrizio Sesana, Franca Davanzo

350. Overdose or drug interaction? Reducing risks when starting and stopping rifampicin therapy
   Linda V Graudins, Michael J Dooley
Poisons centre activities

351. Telephone-based product identification by poisons centers
   Maren Hermanns-Clausen, Herbert Desel, Elke Färber, Carola Seidel, Angelika Holzer, Florian Eyer, Antje Engel, Dagmar Prasa, Erol Tutdibi, Andreas Stürer

352. EPCCASES: Development of an automated case data collection tool for European poisons centres

353. Review of calls concerning human medicine to the poisons center of the northern France: How many calls concern the scope of pharmacovigilance?
   Bea Lelièvre, Marine Auffret, Jacques Caron, Damien Paucelle, Monique Mathieu, Sophie Gautier

354. Cloud and business intelligence technologies in the poison center consulting service and national reporting system
   Miran Brvar, Ernest Zejn

355. TOXBASE® and its use in collecting data on new and uncommon products of interest
   Richard D Adams, Alison M Good, Simon HL Thomas, John P Thompson, A Allister Vale, Michael Eddleston

356. TOXBASE®: Its use in answering poison information enquiries in the United Kingdom
   Gillian Jackson, Alison M Good, Simon HL Thomas, John P Thompson, Allister Vale, Michael Eddleston

357. TOXBASE®: Keeping a poisons information database current and meeting UK demand
   Gillian Jackson, David J Lupton, Alison M Good, Simon HL Thomas, John P Thompson, Allister Vale, Michael Eddleston

358. Organizational peculiarities of poison information and advisory help in Russia
   Yury N Ostapenko, Vladimir I Kazachkov, Konstantin M Brusin, Hugas S Porksheian, Alexander V Sabaev

359. A glimpse of trends in the Poisons Information Centre of Vienna, Austria
   Angelika Holzer, Kinga Bartecka-Mino, Helmut Schiel, Tara Arif, Dieter Genser

Miscellaneous

360. The Global Educational Toxicology Uniting Project (GETUP)
   Anselm Wong, Rais Vohra, Anne-Michelle Ruha, Zeff Koutsogiannis, Kimberlie A Graeme, David M Wood, Paul I Dargan, Anne Creaton, Shaun L Greene
361. Correlating physical exam findings on poisoned patients through Google Glass
   *Peter R Chai, Kavita M Babu, Edward W Boyer*

362. Globalization and international collaboration in toxicology researches: Viewpoint from publications in Clinical Toxicology, 1968 to 2013
   *Ching-Hsing Lee, Chun-Kuei Chen, Meng-Huan Wu*

363. Hard to swallow: Intravenous botulinum toxin A administration
   *Vincent Nguyen, Scott N Lucyk, Silas W Smith, Robert S Hoffman*

364. High-fidelity simulation improves knowledge and self-confidence of junior emergency resident
   *Jiun-Hao Yu, Chih-Chuan Lin*

365. Impact of clinical toxicology in emergency medicine in Spain: Review of articles published in the journal EMERGENCIAS
   *Santiago Nogué, Montserrat Amigó, Òscar Miró*

366. Tattoo-associated granulomatous inflammatory reaction with intensive keloid formation
   *Esther Feistkorn, Kathrin Begemann, Axel Hahn*

367. Hemoglobin anomalies: Unrecognized differential diagnosis of methemoglobinemia
   *Satariya Trakulsrichai, Winai Wananukul, Charuwan Sriapha, Bhakbhoom Panthan, Paisan Jittorntam, Objoon Trachoo*